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resumo Aproximadamente 50% dos doentes com carcinomas musculo 
invasivos de bexiga (MIBC) desenvolvem metástases num período 
de 5 anos após a cirurgia, mesmo quando submetidos a regimes de 
quimioterapia pré- e pós-cirurgia. Assim, surge a necessidade de se 
desenvolverem biomarcadores específicos para identificar fenótipos 
celulares agressivos e terapias diretas baseadas em marcadores 
moleculares. Recentemente, surgiram evidências de que tumores 
de bexiga em estadio avançado expressam sialil-Tn (STn) na 
superfície celular, um antigénio associado a tumores que pode ser 
usado para detetar fenótipos agressivos no cancro da bexiga. Este 
antigénio resulta de uma paragem prematura na O-glicosilação de 
proteínas presentes na superfície celular, e tem demonstrado ser 
capaz de prevenir o reconhecimento imunológico das células 
cancerígenas, evitando a eliminação das células metastáticas, 
modular o fenótipo maligno e induzir a capacidade metastática 
destas mesmas células. No presente estudo, avaliou-se por 
imunohistoquímica a expressão de STn e Ki-67 (marcador de 
proliferação celular) numa série de 96 doentes com cancro de 
bexiga em diferentes estadios. Este estudo demonstrou uma 
associação entre a expressão de STn e a proliferação tumoral e 
invasão. A expressão de STn também foi observada em 
metástases ganglionares e à distância de tumores STn positivos. O 
antigénio STn foi maioritariamente observado em glicoproteínas de 
alto peso molecular (>250 kDa) e em proteínas de baixo peso 
molecular a 25, 15 e 10 kDa. Estas espécies de baixo peso 
molecular predominaram nas metástases ganglionares que também 
não apresentaram proteínas de alto peso molecular, sugerindo uma 
assinatura molecular associada com metastização. De modo geral, 
o antigénio STn apresenta potencial para o desenvolvimento de 
novas terapias contra tumores de bexiga agressivos. Estudos 
futuros deverão ser realizados para determinar a natureza das 
glicoproteínas que expressam o STn e confirmar a possibilidade de 
uma assinatura molecular associada com metastização.  
 A segunda parte do trabalho focou-se na validação de um 
xenógrafo de tumor de bexiga expressando STn, como modelo para 
teste de fármacos e identificação de biomarcadores de prognóstico. 
Um tumor de bexiga musculo invasivo e STn positivo e os 
xenotransplantes resultantes da primeira, segunda e terceira 
passagens foram comparados em relação a proliferação (Ki-67), 
diferenciação (p63 e CK20) e expressão de STn, por 
imunohistoquímica. Os padrões de histologia e imunohistoquímica 
entre o tumor primário e os xenógrafos eram idênticos, revelando 
um grau de similaridade entre o modelo animal e o tumor humano. 
Contudo, os níveis de p53 e Ki-67 aumentaram ao longo das 
passagens enquanto os níveis de STn diminuíram, sugerindo uma 
seleção dos clones mais proliferativos. 
Estas observações possuem uma importância fundamental na 
expansão do conhecimento sobre a relevância clínica do STn no 
cancro da bexiga e na criação dos fundamentos para uma terapia 
baseada neste antigénio. 
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abstract Approximately 50% of muscle invasive bladder cancers (MIBC) 
develop metastasis within 5 years after surgery, despite being 
subjected to pre- and post-surgery chemotherapy regimes. Thus, 
specific biomarkers to target aggressive cell phenotypes and direct 
molecular-based therapy are warranted. Recently, evidences have 
been presented that advanced stage bladder cancers express the 
cell-surface tumor-associated carbohydrate antigen sialyl-Tn (STn), 
which may be used to target aggressive bladder cancer cells. The 
STn antigen results from a premature stop in the O-glycosylation of 
cell-surface proteins and has been found to prevent immune 
recognition, contributing to avoid metastatic cell elimination, 
modulates the malignant phenotype and enhances the metastatic 
ability of cancer cells. In the present study, a series of 96 patients 
with bladder cancer of different stages was screened for STn 
expression and proliferation (over-expression of Ki-67) by 
immunohistochemistry. This showed an association between STn 
expression and tumor proliferation and invasion. STn expression 
was also observed in lymph node and distant metastases of STn 
positive tumors. The STn antigen was mainly detected in high-
molecular weight glycoproteins (>250 kDa) and low-molecular 
weight proteins at 25, 15 and 10 kDa. These low-molecular weight 
species predominated in lymph node mestastasis samples that also 
did not present high-molecular weight proteins, suggesting a 
molecular signature associated with metastasis. Altogether, the STn 
antigen presents potential for the development of new therapies 
against aggressive bladder cancer. Studies should be conducted to 
determine the nature of the STn-expressing glycoproteins and 
disclosing the possibility of a molecular signature associated with 
metastasis. 
 The second part of the work focused on the validation of a STn-
expressing bladder cancer xenograft as a model to drug testing and 
identification of prognostic biomarkers. A STn-positive muscle-
invasive bladder tumor and its first, second and third generation 
xenotransplants were compared in relation to proliferation (Ki-67), 
differentiation (p63 and CK20), aggressiveness (p53) and STn 
expression, by immunohistochemistry. Histological and 
histochemical expression patterns were similar between primary 
tumor and xenografts, highlighting a degree of similarity between 
the animal model and the human tumor. However, p53 and Ki-67 
levels increased along passages while STn decreased, suggesting 
a selection of the most proliferative clones. 
 The generated information is regarded of primary importance to 
expand the knowledge about the clinical relevance of STn in bladder 
cancer and create the rationale for a STn-based therapy. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A ignorância afirma ou nega veementemente. A ciência duvida. 
Voltaire
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Bladder cancer – clinicopathological classification, 
therapeutic challenges and the sialyl-Tn antigen 
Urinary bladder cancer is the fifth most frequent neoplasia in western countries 
(and ninth worldwide), and has the highest treatment costs per patient of all cancers [1–
3]. High recurrence rate and long-term follow-up, as well as repeated interventions, are 
the major causes that turn bladder cancer the costliest to treat among all solid tumors [2, 
4]. 
Most of diagnosed bladder cancer cases in western countries (70-80%) are 
superficial non-muscle invasive carcinomas (NMIBC) that do not reach the muscularis 
propria [3–5]. NMIBC cases include papillary low-grade tumors confined to the mucosa 
(pTa), high-grade papillary lesions, that may invade the subepithelial connective tissue but 
not the muscle (pT1) or high-grade flat lesions termed carcinoma in situ (CIS), as shown in 
Figure 1 [6–8]. High-grade tumors present poorly differentiated cells and higher 
aggressiveness, while low-grade tumors exhibit well differentiated cells. The standard 
treatment for NMIBC is complete transurethral resection (TUR) [4, 5, 7]. Approximately 
10-30% of the patients with NMIBC are at an high risk of recurrence that may be 
accompanied by muscle invasive disease (MIBC), correlated with poor prognosis [3, 9]. 
The risk of recurrence and/or progression is determined by clinicopathological features – 
according to the European Organization for Research and Treatment of Cancer (EORTC), 
this group includes high-grade papillary tumors, CIS and multifocal disease [5, 7]. To 
decrease the risk of recurrence/progression, these patients are submitted to schedule of 
intravesical instillations with attenuated strains of Mycobacterium bovis (the Bacillus 
Calmette-Guérin (BCG) vaccine) [3, 4], after removal of the tumor. This treatment is known 
to promote a strong immunologic response in the bladder that ultimately contributes to 
eliminate the residual tumor [7, 10]. Despite effective in delaying recurrence, one third of 
the patients either do not respond or present intolerance to BCG, 70% of the responders 
relapse within 5 years and approximately 15% progress to muscle invasive disease [7, 8]. 
Moreover, many patients develop chronic cystitis or other side-effects during and after 
BCG therapy [3]. Upon therapeutic failure and/or muscle invasion, the patient is generally 
appointed for cystectomy [4, 5]. Therefore, alternative organ-spearing therapeutic options 
for NMIBC patients that either do not respond or show significant intolerance to BCG 
immunotherapy are warranted. 
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The remaining 20-30% of the newly diagnosed cases worldwide are muscle invasive 
bladder cancers (MIBC), that comprise pT2-pT4 stages (Figure 1) [3, 4]. These neoplasias 
are treated by radical cystectomy [3, 5], and also submitted to pre-and post-cystectomy 
neo-adjuvant chemotherapy, to reduce the risk of metastasis. However, the current 
chemotherapy regime carries significant toxicity, and approximately 50% of MIBC cases 
develop metastasis within 5 years [5, 11].  
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 1 | Extension of the different stages of bladder cancer (NMIBC and MIBC) (reprinted 
from [4]). 
 
At the moment, there is a lack of specific biomarkers to target aggressive cell 
phenotypes in bladder tumors, predict MIBC response to chemotherapy or assist the 
design of optimal treatment schemes, which would translate in better outcomes and 
improved overall survival. Therefore, the identification of these biomarkers is considered 
of main importance, since they may be used to avoid preventive cystectomy and/or reduce 
the chance of poor outcome, greatly improving the management of bladder cancer [3, 11]. 
Recent studies have pointed out that advanced stage NMIBC and MIBC express the 
sialyl-Tn (STn) antigen, a cancer-associated glycan that results from a premature stop in 
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the O-glycosylation of cell-surface proteins [11–13]. This antigen is not present in the 
healthy urothelium, denoting a cancer-specific nature, and has been found to promote the 
invasive and migration potential of bladder cancer cells in vitro  [11]. Given its cell-surface 
nature, STn offers potential to target aggressive bladder cancer cells. However, despite 
these preliminary evidences, the clinical relevance of these alterations, such as the 
association with invasion and metastasis, remains to be verified. Additionally, the proteins 
carrying this alteration remain unknown. Thus, the confirmation of the association of the 
sialyl-Tn antigen with invasion and metastasis is warranted in order to establish the 
rationale for a novel therapeutics. The development of animal models expressing this 
antigen would also greatly benefit such a goal.  
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Protein O-glycosylation in eukaryotic cells 
The sialyl-Tn (STn) glycan can be found as a post-translational modification of O-
glycoproteins at the cell-surface of cancer cells. Glycosylation is the most common post-
translational modification of proteins and plays a pivotal role in structural and functional 
features of these molecules – in fact, virtually, all proteins can be glycosylated [14, 15]. 
Glycans are more complex and diverse in structure and in composition than proteins. 
Furthermore, the glycosylation of proteins is not a template driven event and frequently 
the same protein may assume different glycoforms, making of glycan characterization a 
challenging analytical task [16, 17]. Moreover, glycan structures may vary significantly in 
response to changes in physiological conditions, with implications in cell-cell adhesion, 
cell recognition, activation/modulation of immune response and the activation of several 
intracellular signaling pathways [17, 18]. 
Protein O-glycosylation is a stepwise pathway that begins in the Golgi apparatus of 
eukaryotic cells, in which monosaccharides are added individually and sequentially to 
serine (Ser) and threonine (Thr) residues of proteins by a complex set of enzymes [15, 19]. 
O-glycans are highly expressed in mucins, a class of heavily glycosylated proteins secreted 
by mucosa and some exocrine glands [14, 20]. The high content in VNTR (Variable Number 
Tandem Repeat) regions exhibited by mucins, which are rich in Ser and Thr residues, 
provides the necessary backbone for a bulk of O-glycosylation [14, 20, 21]. As a result of its 
association with mucins, cell surface O-glycans are generally designated as mucin-type O-
glycans; nevertheless, O-glycans can also be found in many other cell surface glycoproteins 
exhibiting Ser and Thr residues [14]. A certain variation of O-glycosylation seems to also 
occur in the nucleus and cytosol, a process termed nuclear O-glycosylation. This nuclear O-
glycosylation is performed by a single N-acetylglucosamine (GlcNAc) residue that binds to 
a serine (Ser)/threonine (Thr), and appears to perform a signaling role similar to protein 
phosphorylation [22, 23]. In addition to mucins, a recent proteomic study has described 
almost 3000 glycosites in over 600 O-glycoproteins, 80% of each from the cell surface, but 
also from the cytoplasm and nucleous. This work greatly expanded the view of the O-
glycoproteome and the array of protein function it may regulate [24]. 
Mucin-type O-glycans synthesis begins with the transfer of an α-N-
acetylgalactosamine (GalNAc) from the donor-nucleotide sugar uridine diphosphate – N-
acetylgalactosamine (UDP-GalNAc) to the hydroxyl group of a residue of Ser//Thr within 
the glycoprotein being synthesized [14, 15, 19]. This reaction forms the simplest mucin O-
glycan – the Tn antigen (GalNAcα-O-Ser/Thr). This structure can be sialylated at O-6 
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position by a ST6GalNAc-I sialyltransferase, originating the sialyl-Tn (STn, Neu5Acα2-
6GalNAcα-O-Ser/Thr) antigen; nevertheless, sialyl-Tn cannot function as substrate for any 
other glycosyltransferase, and thus the elongation of oligosaccharide chain stops (Figure 
2) [14, 18, 20].  
The initial step of O-glycosylation is catalyzed by a family of 20 membrane-bound 
enzymes denominated UDP-GalNAc:polypeptide glycosyltransferases (ppGalNAc-Ts), that 
have distinct but overlapping specificities [15, 19]. This family of enzymes has a C-
terminal lectin domain, which make them unique among all others eukaryotic 
glycosyltransferases [22, 25]. This diversity, as well as the fact that O-glycosylation has no 
consensus sequence to occur, allows a fine tuned control of the initiation of this process in 
a specific cell or even in a specific protein [14, 26].  
When the first step of the synthesis is concluded, a galactose (Gal) residue is 
transferred from an uridine diphosphate - galactosamine (UDP-Gal) donor to the GalNAc 
of the Tn antigen by a specific galactosyltransferase (β(1-3)-galactosyltransferase, C1Gal-
T1 or T-synthase), yielding the most common core structure – core 1, also called T antigen 
or Thomsen-Friedenreich antigen (Galβ1-3GalNAcα-O-Ser/Thr), as shown in Figure 2 [14, 
22, 25]. In 2009, Wang et al. proposed that the active state of T-synthase depends on the 
co-expression of an unusual molecular chaperone localized in the ER, Cosmc [27]. 
Apparently, this chaperone prevents the aggregation and proteasomal degradation of T-
synthase, and is required for the export of the enzyme from the ER, leading to the 
formation of core 1 [27].  
T antigen can be sialylated at O-3 position by a ST3Gal-sialyltransferase, yielding the 
sialyl-3-T antigen (S3T, Neu5Acα2-3Galβ1-3GalNAcα-O-Ser/Thr); this antigen can be 
further sialylated at O-6 position, by a ST6Gal-sialyltransferase, originating the di-sialyl-T 
antigen (diST, Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAcα-O-Ser/Thr) (Figure 2) [14, 20]. 
Alternatively, the GalNAc residue of the T antigen may be sialylated at the O-6 position by 
a ST6GalNAc-sialyltransferase, yielding the sialyl-6-T antigen (S6T, Galβ1-3(Neu5Acα2-6) 
GalNAcα-O-Ser/Thr), which can then originate the diST antigen. Tn and T antigens, as well 
as their sialylated structures, block further elongation of the O-chain, and are generally 
designated simple mucin-type O-glycans [20, 28].  
Core 1 may function as a precursor of other core structures (from core 2 to 8), by the 
addition of different monosaccharides, such as galactose, N-acetylgalactosamine, N-
acetylglucosamine and sialic acids [19, 22]. However, cores 1-4 are the most common in 
humans – in fact, cores 5-8 have been characterized in tissues and appear to be formed 
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through direct modification of the nascent O-GalNAc glycan, but the enzymatic machinery 
underlying this process remains unclear [15, 20, 25].  
Core 2 is synthesized in many epithelial (as intestinal mucosa) and hematopoietic 
tissues by the addition of a branching GlcNAcβ(1-6)-linked residue to core 1, by core 2 
β(1-6) N-acetylglucosaminyltransferases (or C2Gn-T) (Figure 2) [14, 20].  
Core 3 is formed by the addition of a GlcNAc residue by a core 3 β(1-3) N-
acetylglucosaminetransferase (C3Gn-T3) to Tn antigen, and the subsequent addition of a 
GlcNAc residue onto core 3 by a C2Gn-T yields core 4, as represented in Figure 2. Thus, 
the prior synthesis of core 3 is required for the formation of core 4 [19, 20, 25]. 
The extension of core units provides a vast array of glycan structures, and is 
catalyzed by N-β3/4-acetylglucosaminyltransferases (β3/4 Gn-Ts) and/or β3/4-
galactosyltransferases (β3/4 Gal-Ts), leading to the formation of side chains designated 
type-1 (Galβ1-3GlcNAc-R) and type-2 (Galβ1-4GlcNAc-R) chains [14, 19, 22]. These chains 
present a ubiquitous expression, and therefore are widely expressed among epithelial 
tissues. Type-1 and type-2 chains can be modified by the action of fucosyl and 
sialyltransferases, yielding ABO blood group determinants and/or Lewis blood group 
related antigens (Lea, SLea, Lex, SLex, Leb and Ley), which function as terminal structures by 
stopping chain elongation [14, 19, 22]. After O-glycosylation is concluded, the formed 
structures can undergo modifications, such as phosphorylation, sulfation and methylation, 
which constitutes an additional mean for their diversity [22]. 
O-GalNAc glycans are crucial structures for cells viability, once they play several and 
distinct roles in the organism, depending on the structure they present – this structural 
variability allows them to function as signaling, recognition and adhesion molecules [16, 
17, 20]. 
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Figure 2 | Pathways of the biosynthesis of O-GalNAc glycans – synthesis of Tn and STn antigens 
and cores 1 to 4, which are the most common in humans (reprinted from [14]). 
Enzymes: β(1-3)-galactosyltransferase (β3Gal-T); β(1-4)-galactosyltransferase (β4Gal-T); core 3 
β(1-3) N-acetylglucosaminyltransferase (β3Gn-T); core 1 β(1-3)-galactosyltransferase (C1Gal-T1); 
core 2 β(1-6)-N-acetylglucosaminyltransferase (C2Gn-T); UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase (ppGalNAc-T); α2,3-sialyltransferase (ST3Gal); GalNAc α2,6-
sialyltransferase (ST6GalNAc). 
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Regulation of O-glycosylation 
As O-GalNAc glycans are complex and widely diverse structures, their synthesis is 
tightly regulated. However, exactly mechanisms by which this regulation occurs remain to 
be clarified [20, 21]. The regulation of O-glycosylation seems to be dependent on the 
pattern of the enzymes involved in this process – substrate specificity, intracellular 
localization and level of relative activity are the main control factors of O-glycosylation 
[20, 21, 23]. 
Substrate specificity of glycosyltransferases and other enzymes involved in O-
glycosylation allows a restriction of the number of possible O-GalNac glycans that can be 
formed, since these enzymes act in well-defined substrates [20, 25]. On the other hand, 
this specificity reduces the number of pathways by which O-glycans can be synthesized 
[20, 25]. For example, ST antigen can only be generated by the addition of a sialic acid 
residue to T antigen (core 1). The adding of a galactose residue to STn antigen does not 
yield the same structure, since the sialic acid present in STn antigen blocks the action of 
other glycosyltransferases, namely C1Gal-T1 [20]. 
Intracellular localization of glycosyltransferases is another important regulation 
factor of O-glycosylation, which is determined by the physical separation of enzymes 
within the Golgi compartments [25, 28]. These enzimes appear to be arranged in an 
assembly line in the Golgi apparatus – early acting glycosyltransferases occupy the cis-
Golgi, intermediate acting enzymes are localized in the medial Golgi and terminal acting 
enzymes in the trans-Golgi, which allows a tight control of O-glycosylation [20, 28].  
The third major control factor is the level of relative activity of glycosyltransferases, 
that consequently dictate the relative amounts of synthesized O-glycans – the activity of 
two competitive enzymes will determine the nature of the O-GalNAc glycan being 
synthesized, depending on which activity predominates [16, 25]. Besides this competition 
between glycosyltransferases, there is also the influence of other regulatory components, 
namely specific binding proteins required for the activation of glycosyltransferases [20]. 
Co-expression of Cosmc required for the activation of C1Gal-T1 is one example of this type 
of regulatory components [27]. 
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Alterations of O-glycosylation in cancer 
Abnormal protein O-glycosylation is considered a hallmark of malignant 
transformation [14, 20, 21]. Tumor-associated glycans can be found in the surface of 
cancer cells, and therefore are easily accessible to antibodies and lectins [29, 30]. 
Moreover, they are released to the peripheral circulation, either in secreted glycoproteins 
or by shedding from cell surfaces – these features allow them to be explored in various 
serological assays [20, 29]. Therefore, the presence of some tumor-associated glycans in 
serum is nowadays for post-surgical follow-up, to determine disease recurrence, 
progression and/or response to therapeutics [31]. 
Among the most common structural features associated with cancer are the altered 
expression of terminal structures, which includes loss of ABO determinants by secretor 
individuals and changes of Lewis antigenic patterns [20, 28], over-expression of mucins 
[32, 33], particularly MUC1, and incomplete O-glycosylation, yielding low molecular 
weight O-glycans [14, 20].  
The first evidences of alterations in glycosylation patterns of tumor cells concerns 
loss of ABO blood group determinants in gastric cancer [34], and the correlation of the 
degree of A/B determinants deletion with invasion and metastatic spread was then 
described in lung [35] and head and neck [36] carcinomas. Thereafter, the relationship 
between expression of ABH antigens and survival of patients with non-small-cell 
carcinoma of the lung was also studied, and it was concluded that continued A 
determinant expression was correlated with a longest average survival, while A deletion 
was correlated with a reduced overall survival [37]. Nevertheless, correlation between B 
antigen expression and survival rate was not found [37]. Similar results were observed in 
bladder cancer patients with non-invasive and invasive carcinomas [38, 39].  
Changes in Lewis antigenic patterns are related to over-sialylation of terminal 
structures, resulting in an over-expression of SLea and SLex antigens. The referred 
alterations in glycosylation stem from an aberrant expression of the genes encoding sialyl 
and fucosyltransferases, which increases the synthesis of these sialylated structures [14, 
40].  The comprehension of the role of SLea and SLex in cancer begun in 1980s, when 
several studies demonstrated the expression of these antigens in cancer specimens, using 
monoclonal antibodies [41]. Later, in 1991, a study demonstrated the capability of SLea 
and SLex to function as selectin ligands for ELAM-1 (Endothelial Leukocyte Adhesion 
Molecule 1) in endothelials cells [42]. Subsequently, it was also discovered that this 
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mechanism allowed malignant cells to adhere to endothelium, facilitating invasion and 
metastasis [14]. Therefore, over-expression of SLea and SLex in different carcinomas has 
been demonstrated to be correlated with poor prognosis [17, 43].  
Sialylated Lewis antigens can also be released to the bloodstream by malignant cells 
– thus, soluble forms of these antigens are also expressed in high amounts in the blood of 
many cancer patients [20, 21]. Studies based on the average survival of oncological 
patients with gastric carcinomas after surgery revealed that high levels of SLea and SLex 
correlated with lower survival [44, 45]. Based on these features, SLea and SLex are 
currently used in non-invasive assessment of tumor progression and metastatic spread 
[14, 17, 20].  
The over-expression of mucins during neoplastic transformation, namely MUC1 
mucin, has been widely documented [32, 33, 46]. MUC1 is a transmembrane glycoprotein 
with a large extracellular mucin-like domain, formed by 30-90 repeats of 20 homologous 
amino acids rich in O-glycosylation sites [47, 48]. Normally, MUC1 is expressed exclusively 
in the apical domain of epithelial cells; however, on carcinomas cells, the correct topology 
is lost and MUC1 is expressed over the entire cell surface, in abnormally large amounts 
[20, 33]. Since the extracellular domain of MUC1 is long, dense and relatively rigid, due to 
the abundance of O-glycan oligosaccharides, adhesion molecules present in cell surface, 
such as cadherins and integrins, become shielded. Thus, cell-cell and cell-extracellular 
matrix interactions decrease, creating an anti-adhesion effect [33, 49]. Consequently, 
MUC1 mucin has the capability to induce detach of a cell from the primary lesion, leading 
to invasion and metastasis. This process escapes from immune surveillance, because 
MUC1 inhibits the interaction between cytotoxic lymphocytes and the target cell and 
promotes apoptosis of lymphocytes, allowing the detach cell to survive in bloodstream or 
in distant organs [20, 49]. Moreover, the metastatic ability induced by MUC1 is also 
associated with the intracellular domain of the protein, which enters the nucleus and 
initiates the transcription of a set of genes responsible for tumor metastasis [50]. Over-
expression of MUC1 is generally correlated with higher aggressiveness and metastatic 
capability of the tumor [33, 49].  
Serological assays for MUC16 have also been shown the usefulness of this mucin in 
the prognosis of ovarian cancer, in which MUC16 is detected in 80% of the patients. 
Moreover, a correlation between increase/decrease of MUC16 expression and 
regression/progression of the disease has also been observed [14]. Similarly, serological 
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assays for MUC1 mucin in early stage breast cancer specimens have revealed that high 
levels of this glycoprotein are useful in the prognosis of the disease [40, 51]. 
The mechanisms underlying aberrant expression of mucins in malignant 
transformation are still poorly understood; nevertheless, it was suggested that they may 
arise from an up- or down-regulation of the genes encoding mucin proteins [13]. These 
genes may be deregulated in neoplasias originating from tissues where mucins are 
constitutively expressed, or these macromolecules may be ectopically expressed in 
cancers derived from tissues normally devoid of them [13]. 
Another common structural feature in cancer results from a premature stop of O-
chain elongation, normally by sialylation. This event leads to de novo expression of a 
family of low molecular weight O-glycans, that includes Tn and T antigens and their 
sialylated counterparts [14, 20, 21].  
High levels of ST and STn antigens have been observed in several carcinomas, 
namely gastric [18], colon [52], bladder [53], breast [40] and pancreatic [54], whereas low 
levels of expression are found in healthy tissues. Therefore, ST and STn antigens have been 
extensively studied in last decades and are widely assumed as pan-carcinoma biomarkers 
[18, 21, 55].  
T antigen is also considered a pan-carcinoma antigen, once it is substantially over-
expressed in several carcinomas, namely breast [40], bladder [53], colon [52], gastric [56] 
and prostate [57]. Nevertheless, the expression of T antigen is not limited to cancer – it is 
also expressed in normal tissues, although in low levels, since it undergoes further 
glycosylation [52, 56, 57]. In cancer tissues, the glycosylation process becomes incomplete, 
and the expression of T antigen increases significantly. The increment of T antigen 
expression is associated with a worse prognosis in cancer patients [58, 59].  
The incomplete synthesis observed during malignancy can arise from diverse 
alterations in cancer cells. They commonly stem from altered regulation of sialyl and 
glycosyltransferases expression in cancer cells (up/downregulation) [14, 40, 53]. Namely, 
the level of expression of sialyltransferases in breast cancer has been studied as a 
biomarker for the follow-up of oncological patients – apparently, a higher expression of 
ST3Gal-III and ST6Gal-I in human breast tumors is correlated with poor prognosis [60]. At 
the same time, the activity of these enzimes may also be altered in cancer cells [18, 53]. 
Increase of sialyltransferases activity leads to preclude of O-glycosylation, due to the 
blocking effect of sialic acid on glycosyltransferases involved in chain extension [28]. 
Consequently, neoplastic cells express heavily sialylated and truncated O-GalNAc glycans, 
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namely ST and STn antigens, which have an increased ability to bind to adhesion 
molecules present in endothelial cells, such as selectins [18, 28, 53]. Therefore, these 
highly sialylated O-glycans have an enormous invasive potential and metastasis capability 
[18, 28].  
Moreover, these alterations can also stem from a deregulation in the location of 
glycosyltransferases. Gill et al. (2010) [26] suggested a redistribution of ppGalNAc-Ts 
involved in O-glycosylation induced by the activation of Src kinase. This activation 
promotes a relocation of the enzymes from Golgi apparatus to the ER, allowing them to be 
more time in physical contact with potential substrates. Thus, occurrence of O-
glycosylation is dramatically increased, resulting in an enhanced synthesis of truncated O-
GalNAc glycans [26].  
Another possible mechanism underlying the expression of cancer-associated O-
glycans, suggested by Ju et al. (2011) [61], focus on a mutation on the molecular 
chaperone Cosmc, affecting the enzyme responsible for the synthesis of T antigen, T-
synthase. According to Wang et al. (2009) [27], a functional T-synthase depends on the co-
expression of a molecular chaperone, Cosmc. Ju et al. (2011) [61] also demonstrated that a 
mutation in the gene that encodes for Cosmc is responsible by the accumulation of cancer-
associated precursors both in neoplastic lesions, including colon cancer and melanoma-
derived cell lines, and in human cervical cancer specimens.  
Overall, simple mucin-type O-GalNAc glycans are pan-carcinoma antigens, 
associated with malignant phenotypes such as increased invasive and metastatic potential 
– therefore, these structures correlate with poor prognosis [14, 18, 40]. 
 
STn – a pan-carcinoma antigen 
STn detection among healthy tissues is heterogeneous [55, 62]. The expression of 
this antigen was found to be positive in normal salivary glands and in globlet and parietal 
gastric cells of upper digestive tract [55, 63, 64], but not in the esophagus [62]; conversely, 
STn can only be detected in colonic cells after removal of O-acetyl groups [65], and it was 
never found in normal liver and pancreas [62, 66]. In relation to the urogenital tract, STn 
was visible in some uterine and cervix cells, but not in the ovarian ones [55, 62]. Finally, it 
was also detected in some cells of normal lung [62] and breast [67] tissue. It is noteworthy 
that the authors report, overall, that the expression of STn antigen in normal tissues is rare 
Chapter I | Introduction 2013 
 
13 Clinical relevance of the sialyl-Tn antigen in bladder cancer 
 
and/or low, when compared to cancer tissues. Moreover, these studies evidence an 
expression of STn restricted to secreting cells, which suggest that the spread expression of 
this antigen in healthy tissues relates to external fluids of the body [55]. 
STn antigen was also found to be over-expressed by pre-neoplastic lesions, such as 
gastric intestinal metaplasia, breast ductal hyperplasia and chronic ulcerative colitis [18, 
55]. STn was also over-expressed in epithelial benign lesions in ovaries [68] and pancreas 
[69], two tissues devoid of this antigen in the healthy state. Of note, the expression of STn 
in pre-neoplastic pancreas occurred only in the last histological grade relative to benign 
tumor [69]. This suggests that STn over-expression occurs earlier in carcinogenesis in 
tissues that normally express this antigen, rather than in tissues normally devoid of STn 
[55].  
In relation to cancer tissues, STn was reported to be neo- or over-expressed in more 
than 80% of human carcinomas, namely pancreatic [69], endometrial [70], breast [40], 
colon [71] and gastric [72]. Therefore, STn is considered a pan-carcinoma antigen and a 
good tumor marker of carcinogenesis [55]. In line with these observations, several in vitro 
and in situ studies have associated STn antigen with aggressive cell phenotypes [18, 40, 
55]. It has been demonstrated that STn expression promotes major morphological 
alterations on the cell surface glycosylation profile, inducing or preventing the recognition 
by lectins. This process contribute to a cancer phenotype, decreasing cell-cell aggregation 
and increasing extracellular membrane adhesion, migration, invasion and metastasis [18, 
55].  
 
Kakeji et al. (1995) [73] have reported that an increased percentage of STn-positive 
cells was correlated with invasion in gastric cancer. In agreement with this study, Flucke et 
al. (2001) [74] reported a decreased overall survival of the patients with more than 35% 
of STn-positive cells in esophageal cancer, when compared to the low expressing group 
(<35% of STn-positive cells). Recently, Ozaki et al. (2012) [75] described that STn-positive 
gastric cancer cells have demonstrated higher intraperitoneal metastatic ability in 
comparison with STn-negative control in nude mice, resulting in depth of invasion and 
shorter survival. Moreover, Ogata et al. (1992) [76] have previously demonstrated that 
mucins bearing STn antigen are effective inhibitors of natural killer (NK) cells cytotoxicity. 
Thus, it was suggested that over-expression of STn in cancer specimens induces 
impairment in NK cell function of the immune system and, subsequently, that mucins 
expressing STn antigen allow cancer cells to escape from immune surveillance [76].  
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Given its biomarker value, STn was established as a tumor marker in serological 
assays (CA 72-4) [14, 55, 77]. This antigen is present in the bloodstream due to O-
glycoprotein secretion or to cell shedding from tumors, which occurs only when the tumor 
reaches a critical mass. Therefore, the presence of STn in serum is usually detected in 
advanced tumors, and STn is considered a poor prognosis marker [55]. In fact, raised 
levels of serological STn have been associated with decreased overall survival of patients 
with gastric, ovarian and colorectal cancers [14, 55]. Overall, STn is considered a pan-
carcinoma antigen, since it is expressed in the majority of human carcinomas, and it is 
associated with adverse outcome and decreased overall survival of the patients, as 
summarized in Figure 3. 
 
 
Figure 3 | Graphic overview of the expression of STn in cancer (adapted from [55]).  
Top part: reports of positive (blue) or negative (white) expression in healthy, pre-malignant and 
cancer tissues. Bottom part: reports assessing the correlation between STn expression and clinical 
features of cancer, with a significant correlation found in pink and no correlation found in white. 
Size of circles is proportional to the number of published reports. 
Obs.: The positive expression of STn in healthy adult tissue (first line) relates to a sparse or low 
expression, as described in the first paragraph of this section.  
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Given the cancer-associated nature of the STn antigen, a cancer vaccine named 
Theratope, comprehending a synthetic STn disaccharide coupled to a immunogenic carrier 
protein, keyhole limpet hemocyanin (KHL), was developed [55, 78]. Tests in animal 
models and phase II trials for breast and ovarian cancers have showed that the antigen is 
safe and produces a strong immune response against these tumors [78]. However, 
Theratope failed phase III trials for metastatic breast cancers, since it did not improved 
overall patient survival. In a recent review on the subject, Julien et al. (2012) [55] 
discussed that the failure of Theratope was related with the design of the study, namely 
that it disregarded the fact that only 20-30% of the patients with metastatic breast cancers 
expressed the STn antigen. In 2009, nonetheless, Julien et al. [79] investigated the efficacy 
of STn-carrying immunogens to inhibit tumor growth in a MUC1 transgenic mouse model. 
The authors reported that Theratope induced antibodies to STn that recognized the glycan 
carried in a number of glycoproteins. Moreover, a significant delay in tumor growth was 
observed in these mice, and the protection effect seemed to be dependent on STn being 
expressed by the tumor [79]. Altogether, the notion prevails that STn based therapeutics 
may constitute a strategy to control invasion and metastisis, and consequently poor 
outcomes. The fact that it is a cell-surface antigen that may be more easily accessible to 
antibodies and/or other ligands also offers potential in the context of guided therapeutics. 
 
Abnormal O-glycosylation in bladder cancer 
The first reports of alterations in glycosylation of bladder tumors have been 
presented over 40 years ago and relate to the loss of ABO blood group determinants in 
advanced stage carcinomas of secretor individuals (the Se – secretor – locus dictates the 
capability of an individual to express soluble mucins carrying blood group antigens in 
saliva and other tissues). Subsequent studies have shown that malignant transformations 
in the bladder are accompanied by changes in Lewis antigens pattern and over-expression 
of simple mucin type O-GalNAc glycans. Table 1 summarizes the literature on the subject 
in healthy, pre-neoplastic and neoplastic urothelium and its correlation with 
clinicopathological features. The studies focused on the expression of STn, the core antigen 
of this thesis, in the context of bladder cancer will be discussed further forward, in the 
subtopic 2.3.1.. 
Six studies have described the loss of ABO blood group antigens in healthy and 
neoplastic urothelium, as documented in Table 1. Nevertheless, this event is more 
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pronounced in the neoplastic urothelium (44-100%) when compared with the healthy 
urothelium (0-24%). Thorpe et al. (1983) [80] and Summers et al. (1983) [81] have 
correlated the loss of ABO antigens with the invasive potential of the tumor; moreover, 
Limas et al. (1985) [82] have also associated this event with higher grade bladder cancer.  
Altered Lewis antigenic profile has been reported in pre-neoplastic and neoplastic 
urothelium (Table 1). Namely, several authors have studied the expression of Lea in 
bladder tumors. According to Cordon-Cardo et al. (1988) [38], there were no alterations in 
Lea expression patterns with malignant transformations in the bladder. Conversely, Limas 
et al. (1985) [82] reported significantly lower expression of this antigen in healthy 
urothelium (6%), when compared to invasive tumors of the bladder (35%). In agreement 
with this study, Juhl et al. (1986) [39] reported a high expression of Lea antigen in invasive 
bladder carcinomas (93%). Both these studies were performed using a boarder patient 
cohort (n>35) than the one used by Cordon Cardo et al. (n=19), and strongly suggest that 
the expression of Lea is associated with a malignant phenotype of bladder tumor [39, 82].  
The sialylated form of Lea, the SLea antigen, has been observed in bladder dysplasia, 
CIS, non-invasive and invasive carcinomas of the bladder [83]. Nevertheless, no 
correlation was found with invasive or metastatic potential was not established. 
Three studies referred in Table 1 have focused on the expression pattern of Lex 
antigen, and revealed a high percentage of bladder cancer patients expressing altered 
levels of Lex (78-100%). Specifically, Cordon-Cardo et al. (1988) [38] have compared the 
expression pattern of this antigen in healthy urothelium with invasive carcinomas and CIS. 
The study revealed that none of the healthy urohelium specimens expressed Lex; 
conversely, the antigen was observed in invasive carcinomas of the bladder (100%) and 
CIS (79%). Furthermore, the authors proposed that Lex expression could be a reliable 
indicator of malignant transformation in bladder urothelium [38].  
Its sialylated form, SLex expression has also been studied in bladder urothelium, as 
demonstrated in Table 1. According to Numahata et al. (2002) [84], 70% of the invasive 
carcinomas expressed SLex expression. These findings were corroborated by Kajiwara et 
al. (2005) [85] that observed altered SLex patterns in all of the invasive carcinomas 
specimens studied. Both studies referred altered SLex expression as a predictor of invasive 
potential and metastatic outcome.  
Increased levels of truncated O-GalNAc glycans have also been observed in bladder 
cancer (Table 1). Yokoyama et al. (1988) [86] have compared the spontaneous expression 
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of T antigen (48%) with it expression after neuraminidase treatment (cryptic-T antigen 
(18%)), in bladder cancer specimens of various stages. The authors revealed that 70% of 
the T-positive cases presented recurrence, while only 11% of the cryptic-T-positive did. 
Similarly, Summers et al. (1983) [81] reported that those patients who did not 
spontaneously expressed the T antigen (54%), did not suffer invasive recurrences; 
conversely, the patients that expressed spontaneous T antigen (38%) suffered subsequent 
invasive recurrences.  
Tn (79%), STn (3%), T (29%) and cryptic-T (53%) antigens were evaluated by 
Langkilde et al. (1992) [12] in patients with initially non-invasive carcinomas who 
experienced different courses of the disease. No association was found between Tn and 
STn antigens and tumor progression to invasion. Nevertheless, 70% of the patients that 
expressed T antigen and 39% of those who expressed cryptic-T antigen experienced 
invasive recurrence, while the other patients did not [12].  
Furthermore, Limas et al. (1986) [87] demonstrated a crescent expression of T 
antigen through healthy (0%), pre-neoplastic (14%) and neoplastic (11-65%) urothelium. 
Cryptic-T antigen showed a homogeneous expression among all the specimens evaluated 
(78-100%). According to the authors, the spontaneous expression of T antigen is 
associated with aggressiveness of the tumor; moreover, in invasive carcinomas of the 
bladder, this expression correlates with a greater metastatic potential.  
Altogether, these findings suggest that bladder cancer patients who spontaneously 
express T antigen present invasive recurrences more frequently than those who do not 
express this antigen; furthermore, T antigen expression seems to correlate with metastatic 
potential and aggressiveness of the tumor [12, 81, 86].  
The studies presented so far suggest that both pre-neoplastic lesions and bladder 
tumors express altered glycosylation patterns. Some studies also point out that changes in 
cell glycosylation patterns are generally associated with tumor grade, invasive disease and 
metastasis – therefore, they are correlated with poor prognosis [81, 86]. Thus, targeting 
these antigens may allow determining the malignant potential of the tumor and 
controlling the disease. Nevertheless, there studies have been performed in small and 
heterogeneous patient cohorts using different antibodies. Therefore, a careful 
interpretation of the results should be conducted, since several antibodies have shown to 
have affinity for similar structurally-related glycosylated structures [88]. Different 
methodologies have also been used, which may contribute to biased interpretations. 
Chapter I | Introduction 2013 
 
18 Clinical relevance of the sialyl-Tn antigen in bladder cancer 
 
                                                          
1 Evaluated indirectly in exfoliated urine cells 
* May also be found as terminal structures of N-glycans and lipids  
 
 
  
  
n 
Positive cases (%) 
Relates with Technique References 
Tn STn T Cryptic-T Loss of ABO* Lea* SLea* Lex* SLex* 
Healthy urothelium 
 
19 - - - - 16 63 - 0 - - IHQ  [38] 
21 - - - - 24 - - - - - IF  [80] 
35 - - - - 0 6 - - - - RCA  [82] 
24 - - - - 8 - - - - - IHQ  [89] 
30 
6 
- 
- 
- 
0 
0 
- 
80 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
IHQ 
IHQ 
 [87] 
 [11] 
Pre-neoplasia 
          
  
 
Dysplasia1 2 - - - - - - 50 - - - EIA  [83] 
Atypia 7 - - 14 100 - - - - - invasion/metastasis IHQ  [87] 
Neoplastic urothelium 
          
  
 
 
NMIBC  
(except CIS) 
 
39 - - 38 54 54 - - - - invasion IHQ  [81] 
4 - - - - 100 - - - - invasion IF  [80] 
27 - - 11 78 - - - - - invasion/metastasis IHQ  [87] 
42 - - - - - - 64 - - - EIA  [83] 
 
34 
45 
79 
- 
3 
47 
29 
- 
53 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
invasion 
proliferation 
IHQ 
IHQ 
 [12] 
 [11] 
Table 1 | Literature review on the expression of tumor-associated glycans in healthy, pre-neoplastic and neoplastic urothelium. 
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2 Evaluated the urinary levels 
* May also be found as terminal structures of N-glycans and lipids 
 
n 
Positive cases (%) 
Relates with Technique References 
Tn STn T Cryptic-T Loss of ABO* Lea* SLea* Lex* SLex* 
MIBC 
 
44 - - - - - - - - 70 invasion/metastasis IHQ  [84] 
33 - - - - - - 76 - - - EIA  [83] 
19 - - - - - 53 
 
100 - - IHQ  [38] 
1 - - - - 100 - - - - invasion IF  [80] 
48 - - - - 44 35 - - - grade/invasion RCA  [82] 
17 - - 65 88 - - - - - invasion/metastasis IHQ  [87] 
52 - - - - - - - - 100 invasion/recurrence IHQ  [85] 
85 - - - - - 93 - - - invasion/recurrence IHQ  [90] 
93 
19 
- 
- 
- 
74 
- 
- 
- 
- 
44 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
proliferation 
IHQ 
IHQ 
 [39] 
 [11] 
CIS 
 
1 - - - - - - 100 - - - EIA  [83] 
14 - - - - 50 64 
 
79 - - IHQ  [38] 
5 - - 20 100 - - - - - invasion/metastasis IHQ  [87] 
62 
5 
- 
- 
- 
20 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
100 
- 
- 
- 
- 
proliferation 
IHQ 
IHQ 
 [91] 
 [11] 
Not discriminated 
83 - - 48 18 - - - - - grade/recurrence IF  [86] 
32 - - - - - - - 81 - - IHQ  [92] 
78 - - - - - - - 78 - - IHQ  [91] 
Technique’s Abbreviation: 
IHQ – Immunohistochemistry  RCA – Red Cell Adherence Test 
IF – Immunofluorescence  EIA – Enzyme Immuno Assay 
– Not evaluated 
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The STn antigen in bladder cancer 
Despite the cancer-associated nature of the STn antigens, few studies have been 
presented for bladder cancer (Table 1). The first study by Langkilde et al. (1992) [12] 
assessed this antigen on a series of transitional cell carcinomas (currently classified as 
high-grade urothelial cell carcinomas according to WHO guidelines), and in a control 
group, comprehending normal mucosal specimens of patients with non-malignant bladder 
urologic diseases. The authors reported that STn was not expressed by the control group 
and showed a very restricted pattern of expression in bladder tumors. Moreover, no 
association with recurrence and progression were observed [12]. 
In vitro studies performed by Bergeron et al. (1996) [13] showed that mucins MUC1, 
MUC2 and MAUB (mucin antigen of the urinary bladder) isolated from bladder cancer cell 
lines carried the STn antigen. Nevertheless, that expression was not found in tumors.  
Recently, Ferreira et al. (2013) [11] addressed the expression of STn in 6 necropsies 
of normal urothelium, as well as in 69 bladder cancer patients. STn antigen was absent 
from the healthy urothelium, showing the STn tumor-associated expression. The authors 
also reported that approximately 70% of high-grade (HG) bladder tumors over-expressed 
STn. Conversely, only less than 25% of low-grade (LG) tumors over-expressed this antigen 
– altogether, the obtained results suggest that the expression of STn is associated with 
advanced stage bladder tumors, known for an aggressive phenotype. Moreover, Ki-67 
antigen, a proliferation tumor marker, was also assessed in 12 LG and 12 HG tumors from 
the initial series. Only 8% of LG bladder tumors over-expressed Ki-67, as opposed to 75% 
of HG tumors – overall, these findings suggest that the expression of STn is a characteristic 
of proliferating tumors [11]. In vitro studies have further demonstrated that STn 
expression enhanced the invasion capability of bladder cancer cells. 
Despite these observations, little information is available about the biological and 
clinical significance associated with STn expression in bladder cancer. Namely, doubts 
persist about its association with invasion and metastasis, which is of prime importance to 
encourage the development of therapeutics targeting this antigen. 
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Aims and scopes 
The main therapeutic concerns in bladder cancer currently includes the 
management of NMIBC at a high-risk or recurrence with progression, that do not respond 
or show intolerance to BCG immunotherapy, and MIBC [7, 10]. These patients are 
conservatively treated by partial or radical cystectomy with neo- and post-surgical 
chemotherapy to decrease the risk of metastasis. However, over 50% of the patients 
succumb within five years [5, 11]. Due to the limited therapeutic options, the identification 
of a specific biomarker associated with invasion and metastasis could encourage the 
development of new treatments. 
The modification of cells glycosylation patterns is a recognized hallmark of cancer 
[14, 20, 21] and the STn antigen, in particular, presents potential to target malignant cells 
in invasive bladder tumors. It is known that STn contributes to avoid metastatic cell 
elimination in the blood stream by preventing immune recognition [76], modulates the 
malignant phenotype [18] and enhances the metastatic ability of cancer cells [75]. 
Furthermore, this antigen has already been suggested to be over-expressed by 70% of 
high-grade NMIBC and MIBC cases and therefore associated with tumor aggressiveness 
[11]. However, this study was conducted in a rather small and heterogeneous series 
(n=69) comprehending only few MIBC cases. The present work aims to determine the 
association of STn with invasion as well as lymph node and distant metastasis. The second 
part of the work focuses on the validation of a STn-expressing bladder cancer xenograft 
model to support drug testing. The generated information is regarded of primary 
importance to expand the knowledge about the clinical relevance of the STn antigen in 
bladder cancer and create the rationale for a STn-based therapy. 
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Overview 
The first part of the project devotes to verify the association of the STn antigen with 
invasion in a series of 96 primary bladder tumors including different stages of the disease 
(Ta, T1, T2, T3 and T4). This series will also be characterized according to the degree of 
proliferation, based on Ki-67 expression. Moreover, STn expression will be evaluated in a a 
smaller and independent series of 21 bladder tumors isolated by radical cystectomy, 
presenting lymph node (17 cases) and distant metastasis (6 cases). This will allow 
determining the association of the STn antigen with metastasis. Finally, glycoproteins will 
be extracted from bladder tumors and metastasis to disclose the STn-expressing 
glycoprotein profiles. 
The second part of the thesis devotes to the validation of a STn-expressing bladder 
cancer xenograft model in nude mice, by immunohistochemistry and Western blot. Such 
model is regarded of primary importance to identify drugs and treatment regimens that 
would better serve patients with STn-positive MIBC, as well as a platform to identify 
markers of tumor response and resistance to chemotherapic agents. 
An overview on the analytical strategy adopted is presented in Figure 4. 
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Figure 4 | Overview on the analytical approach. FFPE – formalin fixed paraffin embedded; MoAb 
– monoclonal antibody; CK20 – cytokeratine 20.
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Sialyl-Tn over-expression is associated with invasion and 
metastasis in bladder cancer 
Abstract  
Introduction: Approximately 50% of muscle invasive bladder cancers (MIBC) develop 
metastasis within 5 years after surgery, despite being subjected to neo- and post-surgery 
chemotherapy regimes. Thus, specific biomarkers to target aggressive cell phenotypes and 
direct molecular-based therapy are warranted. Recently, evidences have been presented 
that over 70% of advanced stage bladder cancers expressed the cell-surface tumor-
associated carbohydrate antigen sialyl-Tn, which may be used to target aggressive bladder 
cancer cells. Objective: Determine the association of the STn antigen with invasion and 
metastasis and therefore contribute to determine the clinical relevance of this antigen in 
bladder cancer. Methods: The study included 96 patients with bladder cancer of different 
stages.  Moreover, 21 cases with lymph node metastasis, distant metastasis or both were 
also included, as well as the correspondent primary tumors. All cases were screened for 
STn expression by immunohistochemistry. The series of 96 tumors was further 
characterized in relation to their degree of proliferation based on Ki-67 expression. The 
STn glycoprofilling of primary tumors and metastasized ganglia was evaluated by Western 
blot. Results: All STn-positive tumors presented a proliferative phenotype; however, this 
antigen was mainly absent from proliferation areas of the tumor. STn expression was 
found associated with invasion of the basal, muscle and fat layers and STn expressing cells 
were frequently observed in invasion fronts. STn expression was also present in lymph 
node and distant metastasis. The STn antigen was mainly observed in high molecular 
weight glycoproteins (>250 kDa) and what appears to be its proteolysis products between 
25 and 10 kDa. These low molecular weight species predominate in lymph node 
mestastasis samples that also do not present high molecular weight proteins, suggesting a 
molecular signature associated with metastasis.  Conclusions: The STn antigen is 
associated with tumor invasion and can be observed in lymph node and distant 
metastasis, offering potential for the development of new therapies against aggressive 
bladder cancer. Studies should be conducted to determine the nature of the STn-
expressing glycoproteins and disclosing the possibility of a molecular signature associated 
with metastasis and its biological significance. 
Keywords:  invasive bladder cancer, metastasis, sialyl-Tn, glycosylation 
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Introduction 
Bladder cancer is the fifth most common cancer in Western society [1–3] and 
presents the highest recurrence rate among solid tumours and poor prognosis when the 
tumour invades the muscularis propria [2, 4].  
Approximately 10% of newly diagnosed cases are muscle invasive bladder cancers 
(MIBC). Furthermore, approximately 50% of non-muscle invasive bladder tumors 
(NMIBC) comprehending high-grade papillary tumours, carcinoma in situ and multifocal 
and/or recurrent lesions progress to MIBC if left untreated. Although BCG immunotherapy 
has improved the management of these patients, 10-20% of the patients still progress 
after treatment [10].  
Muscle invasive bladder cancers (MIBC) are submitted to pre- and post-cystectomy 
adjuvant chemotherapy; despite this, approximately 50% of these cases develop 
metastasis within 5 years after surgery [5, 11]. Thus, at the moment, there is a lack of 
specific biomarkers to target aggressive cell phenotypes and direct molecular-based 
therapy, which may be used to avoid preventive cystectomy and/or reduce the chance of 
poor outcome [3]. In this context, recent studies have demonstrated that cell-surface 
cancer-associated carbohydrates antigens can be used for selective target delivery. 
It has been long described that aggressive urothelium cancers in individuals of the 
secretor phenotype lose the ability to express cell-surface ABO(H) blood group 
determinants, reflecting profound alterations in glycosylation pathways [20, 28]. 
However, little is known about the glycosylated structures formed thereafter. Following 
these observations, we recently described that approximately 70% of high-grade bladder 
tumours expressed the sialyl-Tn (STn) that results from a premature stop in the O-
glycosylation of cell-surface proteins [11]. Conversely, less than 25% of the low-grade 
cases over-expressed the STn antigen.  Studies in vitro have further demonstrated that STn 
expression promoted the motility and invasive potential of bladder cancer cells [11]. 
Altogether, these findings suggested that STn expression may be associated with tumour 
invasion and metastasis; however, this remains to be verified. Herein, we devoted to 
determine the association of STn with invasion and metastasis in bladder tumours. This 
will help to determine the potential of this epitope in the context of novel therapeutics for 
bladder cancer.  
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Materials and Methods 
Population 
Ninety six bladder cancer patients treated at the Portuguese Institute of Oncology 
(IPO-Porto) between 1998 and 2010 were enrolled in this retrospective study. This 
comprehends 82 males and 14 females ranging in age from 38 to 92 years (median of 69.5 
years). Forty seven bladder tumors were histologically classified as superficial non-muscle 
invasive bladder cancer (NMIBC; pTa and pT1) and 49 as muscle-invasive tumors (MIBC; 
pT2-pT4); moreover, 16 cases were classified as low-grade and 80 as high-grade, 
according to the 2004 WHO stage and grading criteria, respectively. Twenty-one primary 
bladder tumors showing lymph node metastasis (17 cases) and distant metastasis (6 
cases) were also involved in this study. The average follow up time period was 31.5 
months (0 – 79 months). Cystectomy was performed in 64 (66.7%) patients while the 
other 32 (33.3%) were submitted to transurethral resection.  
 
Expression of STn in bladder tumours 
Formalin fixed paraffin embedded (FFPE) tissue sections were screened for STn and 
Ki-67 by immunohistochemistry, using the avidin/biotin peroxidase method, as described 
by Ferreira et al. (2013) [11]. Briefly, 3 µm sections were deparaffinised with xylene, 
rehydrated with graded ethanol series, microwaved for 15 minutes in boiling citrate buffer 
(10 mM Citric Acid, 0.05% Tween 20, pH 6.0), and exposed to 3% hydrogen peroxide in 
methanol for 20 minutes. The expression of STn was then evaluated using anti-STn mouse 
monoclonal antibody, clone TKH2 [93], that identifies both single and clustered STn 
residues [65], whereas Ki-67 was evaluated using monoclonal mouse anti-human Ki-67 
antibody, clone MIB-1 (Dako). After blockage with BSA (5% in PBS), the antigens were 
identified with VectastainEliteABC peroxidase kit (Vector Laboratories) followed by 
incubation with 3,3-diaminobenzidine tetrahydrochloride (DAB, Dako). Finally, the slides 
were counterstained with haematoxylin for 1 minute. Positive and negative control 
sections of intestinal metaplasia were tested in parallel. The negative control sections 
were performed by adding BSA (5% in PBS) devoid of primary antibody. STn positive 
tissues were also treated with a -neuraminidase from Clostridium perfringens (Sigma 
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Aldrich), as previously described by Marcos et al. (2011) [94], in order to remove the sialic 
acid. The desialyated samples were thereafter screened for STn.   
The STn and Ki-67 expression were assessed double-blindly by two independent 
observers and validated by an experienced pathologist. Whenever there was a 
disagreement, the slides were reviewed, and consensus was reached. Tumours were 
classified as STn-positive when immunoreactivity with anti-STn TKH2 antibody was 
observed in more than 5% of tumor cells. Tumours were classified as proliferative 
whenever Ki-67 expression was higher than 18%, as described by Santos et al. (2003) 
[95].  
 
Protein extraction and Western blot 
Proteins were extracted from FFPE tissues using the Qproteome FFPE tissue kit 
(Qiagen). The amount of protein in each extract was estimated with DC protein assay kit 
(BioRad). Protein lysates were then separated by 4–16% gradient SDS–PAGE under 
reducing conditions and transferred onto 0.45 µm nitrocellulose membranes (GE 
Healthcare). Membranes were blocked with 1% carbohydrate depleted carbo-free solution 
(Vector Lab) for 1 hour at room temperature, incubated overnight at 4ºC with anti-STn 
TKH2 monoclonal antibody in culture supernatant, washed with TBS-T for 30 minutes, 
and finally incubated for 45 minutes with goat anti-mouse IgG1 heavy chain horseradish 
peroxidase conjugate (Abcam; 1:35,000 in TBS). After washing, the bound antibodies were 
revealed by chemiluminescence using the ECL Prime Kit (BioRad). Beta-actin expression 
determined with rabbit anti-beta Actin polyclonal antibody (Abcam) was used to control 
protein loads.  
 
Statistical analysis 
Statistical data analysis was performed with IBM Statistical Package for Social 
Sciences—SPSS for Windows (version 20.0). Chi-square analysis was used to compare 
categorical variables.  
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Results  
A series of 96 primary bladder tumors was screened for the expression of the STn 
antigen, by immunohistochemistry, to determine associations with invasion. The tumors 
were further characterized in relation to their degree of proliferation based on Ki-67 
expression. The association of STn with metastasis was assessed in a small series of 21 
primary bladder tumors showing metastized ganglia (n=17) and/or distant metastasis 
(n=6). The STn glycoprofilling of primary tumors and metastasized ganglia was also 
evaluated by Western blot. 
 
Association of STn expression with invasion and proliferation 
All of the STn expressing cells presented membrane and cytoplasmic staining 
(Figure 7), in accordance with previous reports from Ferreira et al. (2013) [11]. STn 
expression was mainly observed in highly undifferentiated cells characterized by high 
nuclear to cytoplasmatic ratio. Control tissue sections, subjected to treatment with an α-
neuraminidase that removes sialic acids, failed to present reactivity with monoclonal 
antibody TKH2, thereby confirming the specificity of the immunostaining. 
As can be observed in Figure 5, STn was mainly expressed by tumors showing 
invasion of the lamina (T1; 60%) and the muscularis propria (≥T2; approximately 60-
90%); conversely, the percentage of positive Ta was lower than 30% (p<0.001).  The 
presence of the STn antigen was statistically associated with MIBC when compared to 
NMIBC (p=0.001), represented in Figure 6. Furthermore, STn expression was also 
statistically associated with high-grade tumours (p=0.012; data not shown).  
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Figure 5 | Association between STn expression and tumor stage. STn is mainly expressed by 
tumors showing invasion of the lamina (T1, n=20) and the muscularis propria (≥T2, n=49). 
Conversely, the percentage of STn-positive Ta (n=27) is lower than 30%. p<0.001 (Chi-square test). 
 
 
 
 
 
 
 
 
 
Figure 6 | Association between STn expression and NMIBC and MIBC. About 80% of MIBC 
(n=49) cases were STn-positive, contrasting with less than 60% of NMIBC (n=47) cases. p=0.001 
(Chi-square test). 
 
Adding to these statistical associations with invasion, STn-positive cells could be 
observed in invasive areas of the tumor, reinforcing a possible role of this antigen in 
invasion (Figure 7). 
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Figure 7 | Expression of STn in bladder tumors. A) and B) Magnification showing 
undifferentiated tumor cells (high nuclear/cytoplasmatic ratio), with membrane and cytoplasmatic 
STn+ staining; C) High-grade papillary tumor showing invasion of the lamina propria and extensive 
STn positivity; D) MIBC highlighting extensive STn expression including in invaded areas of the 
muscle layer. 
 
It is also noteworthy that all of the STn-positive bladder tumors studied 
(approximately 60%) presented a proliferative phenotype. However, as shown by Figure 
8, STn was mainly expressed in non-proliferative tumor areas, which reinforced previous 
observations by Ferreira et al. (2013) [11]. 
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Figure 8 | Expression of STn and Ki-67 in bladder tumors. The marked areas highlight that STn 
is mainly observed in non-proliferative areas of proliferative tumors, with some overlapping zones. 
 
Association of STn expression with lymph node and distant 
metastasis 
The association of STn with metastasis was screened in a small series including 21 
primary bladder tumors, 17 of each with available metastized ganglia and 6 distant 
metastasis. Approximately 88% of the metastized ganglia (15/17) and all of the distant 
metastasis (6/6) screened for this antigen were STn-positive (Figure 9). Furthermore, the 
STn antigen was over-expressed in 93% of the tumors with lymph node metastasis 
(14/15), as also shown by Figure 9. In agreement, the two metastized ganglia which were 
STn-negative also presented primary tumors STn-negative. Therefore, a high STn 
expression in the tumor is associated with lymph node metastasis (p=0.029). As illustrated 
by Figure 9, it is also noteworthy that all of the tumors presenting distant metastasis 
(6/6) over-expressed STn. Figure 10 highlights the extensive STn+ staining in both lymph 
node and distant metastasis. Furthermore, tumor cells with membrane and cytoplasmatic 
STn expression are also evidenced in Figure 10. Altogether, these data suggest the 
association of the STn antigen with the metastization process. 
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Figure 9 | Expression pattern of STn in primary bladder tumors (MT, main tumor) and the 
correspondent lymph node (LNM) and/or distant metastasis (DM). The graphical matrix 
highlights an over-expression of the STn antigen in the majority of the metastized ganglia (88%) 
and in all cases of distant metastasis (100%), suggesting an association between STn and the 
metastatic event.  
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Figure 10 | Expression of STn in lymph node and distant metastasis. A) and B) Magnification 
showing tumor cells with membrane and cytoplasmatic STn+ staining. C) Lymph node metastasis 
evidencing localized STn expression. D) Distant metastasis showing an intense STn+ staining. E) 
Lymph node metastasis highlighting locally extensive STn expression. F) Intense STn+ staining in a 
biopsy of a distant metastasis. 
Lymph node metastasis Distant metastasis 
Chapter IV | Sialyl-Tn over-expression is associated with  
invasion and metastasis in bladder cancer 
2013 
 
41 Clinical relevance of the sialyl-Tn antigen in bladder cancer 
 
STn glycoprofiling  
Proteins were extracted from nine STn positive bladder tumors (T1, n=2; T2, n=3; 
T3, n=3; T4, n=1) and two ganglia presenting metastasis that were isolated and blotted 
with an anti-STn monoclonal antibody, in an attempt to characterize the protein 
expression pattern for this antigen.  
Figure 11 demonstrates the staining pattern for 7 out of the 9 primary bladder 
tumors studied, as well as the two ganglia. A band was visible at 250 kDa in almost all of 
the primary tumors (including the two tumors not shown in Figure 11), especially in the 
first T1 and T4 cases. This band is concordant to the presence of mucins (MUC), possibly 
MUC1, a high-molecular weight transmembrane protein previously reported to be one of 
the main proteins expressing the STn antigen [18, 66, 75].  
The western blot also presented three low-molecular weight bands at 25, 15 and 10 
kDa, with the exception of the proteins extracted from the T4 tumor and the two tumors 
not represented in Figure 11. Noteworthy, the high-molecular weight band was absent in 
the lanes corresponding to the proteins extracted from the two ganglia, denoting a 
metastasis-associated profile. 
As highlighted by Figure 11, samples presenting higher expression of MUC 
presented low abundance of 25, 15, and 10 kDa proteins (such as the first T1, the second 
T3 and the T4 tumors visible in the figure). Conversely, samples expressing low amounts 
MUC presented a high abundance of low-molecular weight proteins (namely the first T2 
and T3 and the two ganglia of the figure). It is likely that low-molecular weight bands may 
correspond to products of proteolysis of MUCs – nevertheless, this hypothesis should be 
further explored.  
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Figure 11 | STn expression pattern in protein lysates from bladder tumors (T1-T4, n=9) and 
ganglia (n=2). An intense band at approximately 250 kDa is present in 7 out of the 9 tumors, 
suggesting its association with mucins, as previously reported by other authors [18, 66, 75]. These 
bands were not observed in the ganglia. 6 out of the 9 tumors also presented low-molecular weight 
bands spanning 25-10 kDa. The optical density of the bands was estimated and normalized in 
relation to beta-actin, previously observed to be a stable housekeeping gene in bladder cancer cells 
[11]. The bands were then classified in relation to their intensity for comparison purposes. The 
figure shows that samples presenting higher levels of high-molecular weight proteins also present 
lower levels of 25, 15, and 10 kDa proteins and vice-versa. These observations suggest that low-
molecular weight proteins may be proteolysis products. Noteworthy, lymph node metastasis 
samples only present low-molecular weight proteins, suggesting a molecular signature associated 
with metastasis. 
 
The ratio between low-molecular weight proteins and MUC expression in primary 
tumors was then estimated and the samples were classified as low or high according to 
their distribution around the median value.  As highlighted by Figure 12, the majority of 
(-) not expressed; (+) expressed; the number of “+” symbols relates with the intensity of expression 
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the samples classified as high (n=5) presented metastasis whereas in the group classified 
as low (n=4) none of the samples presented metastasis, suggesting that the predominance 
of low-molecular weight species in relation to mucins may dictate the potential for disease 
dissemination.  
 
 
 
 
 
 
 
Figure 12 | Ratio between low-molecular weight proteins and MUC expression in primary 
tumors. As highlighted, the majority of the cases with a high ratio (corresponding to a high 
expression of low-molecular weight proteins and a low expression of MUCs) developed metastasis. 
On the other hand, all of the cases presenting a low ratio (high expression of MUCs and low 
expression of low-molecular weight proteins) did not developed metastasis. The predominance of 
low-molecular weight species in relation to mucins seems to dictate the ability of the tumor to 
metastize. 
 
Discussion 
The STn antigen is frequently over-expressed in human carcinomas as a reflection of 
significant alterations in the O-glycosylation pathways of cell-surface proteins and the 
over-expression of heavily O-glycosylated proteins, namely mucins. This antigen has been 
recognized to modulate immune responses and impair protein-protein interactions, 
promoting higher cell motility and metastic capability [18, 55]. In line with these 
observations, our group recently reported that the STn antigen was over-expressed in 
approximately 70% high-grade NMIBC and MIBC, denoting its association with advanced 
stage bladder tumors, known for an aggressive phenotype and decreased overall survival 
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[11]. Nevertheless, this study was conducted in rather small and heterogeneous patient 
cohort (n=69) comprehending low-grade and high-grade non-muscle invasive papillary 
tumors, CIS and MIBC. The present work now devoted to validate the preliminary findings 
by Ferreira et al. (2013) in a broader series [11], and also to determine the association of 
STn expression with metastasis. 
This work, comprehending a series of 96 NMIBC and MIBC primary bladder tumors, 
now reinforces the association of STn expression with invasion [11]. Although STn 
expression has been considerably studied in other carcinomas, namely gastric [63] and 
colorectal [96], where it is associated with poor prognosis, the assessment of this antigen 
in a large series of bladder tumors is being addressed for the first time. Culminating these 
observations, STn-positive cells were observed in invasive areas of the tumor, further 
suggesting a role of this antigen in invasion. Similar conclusions in an in vitro model of 
gastric cancer were described by Pinho et al. (2007) [18]. The authors assessed the role of 
STn in invasion in human gastric carcinoma cells transfected with ST6GalNAc-I 
(expressing mostly STn and designated MST6-I), ST6-GalNAc-II (expressing mostly S6T 
and designated MST6-II) and mock-transfected and reported a 2.5-fold increase in the 
invasion ability of MST6-I cells when compared to the wild type.  Moreover, it was 
observed an anti-invasion effect by incubation of the cells with anti-STn monoclonal 
antibody TKH2, confirming that the invasion capability is mediated by the STn antigen. 
Altogether, our results reinforce the apparent association between STn expression and the 
invasion ability of bladder tumors, confirming the potential of this antigen as a prognostic 
biomarker in the bladder cancer context. 
The primary bladder tumors were further characterized in relation to proliferation, 
based on Ki-67 expression, by immunohistochemistry. Ferreira et al. (2013) [11], using 
the same procedure, reported a percentage of 42% Ki-67 positive tumors, in which 38% 
were high-grade tumors, confirming na high proliferation rate of high-grade tumors. 
Moreover, since the expression pattern of STn correlated with high-grade tumors, Ferreira 
et al. (2013) [11] highlighted an association between proliferative phenotypes and STn 
expression. In agreement with these results, we have also observed that all of the STn-
positive bladder tumors from our series were Ki-67 positive. Furthermore, in all STn-
positive tumors, the antigen expression was mainly seen in areas that did not express Ki-
67, although some overlapping areas were present. This indicates that STn is mostly 
expressed in non-proliferative areas of the tumor, also confirming the observations made 
by Ferreira et al. (2013) [11]. Reflecting the interdependence between STn and Ki-67 
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expression, the majority of non-proliferative tumors (Ki-67 negative) were also STn-
negative. Overall, it can be highlighted that STn is associated with tumor proliferation, 
characteristic of high-grade tumors. 
The STn antigen was also observed in 88% of metastized ganglia and all distant 
metastasis were positive for this antigen; furthermore, 93% of the correspondent primary 
bladder tumors were also STn-positive. Altogether, this data suggests that the expression 
of STn may reflect on the mobility of cancer cells and the capability to metastize. The 
association of STn expression with metastasis has been demonstrated in vivo and also in 
vitro in gastric [75] and breast [97] cancer cells. Namely, Ozaki et al. (2012) [75] have 
assessed the metastatic ability of a human gastric cancer cell line expressing STn in a 
mouse model. The obtained results showed a prognostic improvement of mice by repeated 
injections of anti-STn monoclonal antibody B72.3. It was observed an anti-tumor and anti-
metastatic effect of B72.3, suggesting the possible involvement of STn in the enhancement 
of metastatic ability of gastric cancer cells, which is in agreement to our results. In sum, 
the generated data highlight the association of STn with lymph node and distant 
metastasis, corroborating the aggressive nature and clinical relevance of this antigen in 
the bladder cancer context. 
Despite the association of STn with a poor prognosis in a variety of cancers [18, 40, 
96], scarce information is available about the glycoproteins that carry this post-
translational modification [13]. Thus, the characterization of protein expression patterns 
for STn was established as a secondary goal of this study. In an explorative approach, 
proteins from 9 primary bladder tumors and 2 metastasized ganglia were evaluated by 
Western blot for STn expression. An intense staining pattern at 250 kDa is constant among 
almost all of the primary tumors. This staining is concordant to the presence of mucins, 
namely MUC1, a high-molecular weight (MW) transmembrane glycoprotein, reported to 
be heavily O-glycosylated and one of the main carriers of STn [18, 66, 75]. Analogous 
results were reported by Pinho et al. (2007) [18], which have identified high MW proteins 
as the major carriers of STn by Western blot in a human gastric cancer cell line over-
expressing this antigen. Furthermore, the authors confirmed through 
immunoprecipitation that one of the major glycoproteins expressing STn was MUC1. Ozaki 
et al. (2012) [75], using a similar approach, have also identified MUC1 as one of the main 
carriers of STn in a human gastric cancer cell line expressing STn in a mouse model. These 
results lead us to hypothesize that the intense staining band at 250 kDa present in our blot 
refers, possibly among other high MW proteins, to MUC1 mucin. MUC1 over-expressing 
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the STn antigen in cancer cells is known to suppress cellular aggregation, due to the 
presence of highly O-glycosylated and sialylated structures, which mask the majority of 
cell-surface molecules and disturb its interaction with the macromolecules on adjacent cell 
membranes [98]. Moreover, sialylated MUC1 has already shown to inhibit the interaction 
between cytotoxic lymphocytes and target cells, leading to the apoptosis of lympochytes. 
This process induces detach of cells from primary lesions, contributing to invasion and 
metastasis [20, 49]. Therefore, according to the literature, it is suggested that high levels of 
expression of sialylated MUC1 are associated with an aggressive phenotype, reinforcing 
our results.  
The majority of the cases also presented low MW proteins, namely at 25, 15 and 10 
kDa that where decreased in samples expressing high levels of STn in mucins. Conversely, 
in samples presenting higher expression of these proteins, the levels of mucins were 
decreased. Altogether, this data also suggests that low MW species may result from the 
proteolysis of mucins. Noteworthy in the ganglia only low MW proteins could be observed, 
denoting a molecular profile associated with metastasis. Reinforcing a possible association 
between the over-expression of low MW proteins with metastasis, the majority of the 
primary tumors presenting elevated ratios of low MW proteins/MUC presented 
metastasis, irrespectively of their stage. On the other hand, all cases with low ratio did not 
present metastasis, including tumors staged T3 and T4. In line with these observations, 
Lau et al. (2012) [50] has recently identified a pathway of EGF (epidermal growth factor)-
dependent metastasis that requires a Src (tyrosine-protein kinase)-mediated MUC1 
proteolysis, without impact on primary tumor growth. The authors report that EGF 
stimulation induces MUC1 cleavage, leading the MUC1 cytoplasmic domain 
transmembrane subunit (MUC1.CD) to translocate to the nucleus, where it promotes the 
expression of metastatic genes. These results show that EGFR and Src activity, and 
consequently proteolytic cleavage of MUC1, contribute to tumor metastasis, which is 
concordant to our results. These observations need to be validated in a large number of 
patients and efforts should be conducted to identify these glycoproteins and disclose their 
contribution to malignancy.  
In conclusion, our results reinforced previous observations made by Ferreira et al. 
(2013) [11] in respect to the association of STn with invasion and proliferation in bladder 
cancer. An association of STn with lymph node and distant metastasis was also observed, 
corroborating the aggressive nature of this antigen and its potential as a prognostic 
biomarker in the bladder cancer context. We have also observed that high MW proteins 
Chapter IV | Sialyl-Tn over-expression is associated with  
invasion and metastasis in bladder cancer 
2013 
 
47 Clinical relevance of the sialyl-Tn antigen in bladder cancer 
 
are the major carriers of STn in bladder cancer, in agreement with results from previous 
studies in gastric [18, 75] and breast [97] cancers. More important, we suggest that a 
proteolytic cleavage of high MW proteins in bladder tumors originates a pattern of low 
MW proteins that seems to be associated with a metastatic phenotype. 
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Patient-derived sialyl-Tn positive invasive bladder 
cancer xenografts in nude mice: an exploratory model 
study 
(This chapter corresponds to a manuscript submitted to Anticancer Research) 
Abstract 
Introduction: Over 70% of muscle invasive bladder cancers (MIBC) express the cell-
surface antigen sialyl-Tn (STn) that promotes motility and invasive potential of tumor 
cells. Effective drug testing models to optimize therapy against these tumors are 
warranted. Objective: Validate a patient-derived bladder cancer xenograft model in nude 
mice to test drugs against STn-positive bladder tumors. Methods: Fragments of STn-
positive MIBC were subcutaneously engrafted into nude mice and expanded until the third 
passage. Histology and immunoexpression of tumor markers (p53, p63, Ki-67,CK20,sTn) 
were analyzed to evaluate tumor phenotype maintenance. Results: Tumor take rate was 
low in the first passage (1/9) but increased and became consistente in the third passage 
(13/13), therefore suitable for drug testing. Histology and immunoexpression patterns 
were similar between primary tumor and xenografts. However, p53 and Ki-67 levels 
increased along passages suggesting a selection of more proliferative clones. STn 
expression, even though decreased, was preserved in xenografts. Conclusions: We 
describe the first patient-derived STn-positive xenograft model to be used for drug testing 
and identification of prognostic biomarkers.  
 
Keywords:  human xenografts, urothelial cancer, drug testing, animal models, sialyl-Tn, 
glycosylation.  
Abbreviations: 
H&E: hematoxylin and eosin; MIBC: muscle invasive bladder cancer; STn: sialyl-Tn; FFPE, 
Formalin-Fixed, Paraffin-Embedded.  
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Introduction 
Bladder cancer is the fourth most common genitourinary cancer among men and the 
seventh in women, with an estimated 386,365 new cases  and 150,165 deaths each year  
[99].  
Although only one-third of the newly diagnosed bladder carcinomas are advanced at 
presentation (clinical stage cT2-T4a), 15–30% of high-grade superficial tumors progress 
to muscle-invasive cancers (MIBC), usually within 5 years  [100]. The standard treatment 
for patients with MIBC is radical cystectomy with removal of regional lymph nodes  [101]. 
However, up to 50% of these patients will relapse with progression to metastatic disease 
associated with poor survival.  [102]. In order to improve this poor outcome, neoadjuvant 
chemotherapy with therapeutic regimens containing cisplatin, such as MVAC 
(methotrexate, vinblastine, doxorubicin and cisplatin) or GC (gemcitabine and cisplatin) 
are recommended  [101, 103]. Previous studies showed that neoadjuvant platinum-based 
chemotherapeutics were associated with an absolute risk reduction of 8% in a 5-years 
follow-up  [104]. However, significant variations in the natural history and responses to 
treatment are seen between MIBC tumors with identical histological features, reflecting 
the heterogeneity of the constituent tumor cells  [105]. At the moment, there are no 
biomarkers to predict MIBC response to chemotherapy or assist the design of optimal 
treatment schemes, which would translate in better outcomes, reduced toxicity and 
improved overall survival.  
Reflecting the molecular heterogeneity of invasive tumors, we recently reported that 
approximately 70% of MIBC express the sialyl-Tn (STn) carbohydrate antigen, resulting 
from a premature stop in proteins glycosylation. The STn antigen was observed in highly 
proliferative tumors and found to promote cell motility and invasive capability  [11].  The 
increased expression of ST6GalNac-I leads to STn biosynthesis  [106] in several epithelial 
cancers (eg. gastric, pancreatic, colorectal, ovarian and breast cancers) and is usually 
associated with poor prognosis  [55, 94]  Additionally, the STn antigen contributes to 
avoid metastatic cell elimination in the blood stream by preventing immune recognition  
[107], modulates the malignant phenotype  [18] and enhances the metastatic ability of 
cancer cells  [75]. Therefore, efficient therapies against STn-positive bladder tumors are 
warranted; furthermore, the response of these particular tumors phenotypes/clones to 
available chemotherapy agents remains unknown.  
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The development of non-human models expressing the STn antigen has been a 
particularly challenging enterprise.  Despite the pan-carcinoma nature of this antigen  [55] 
several well established cancer cell lines of different organs either do not express or lose 
the capability to present this type of glycosylation  [11, 97], denoting a dependence of the 
tumor microenvironment  [11]. In an attempt to overcome this limitation bioengineered 
cell lines to express the STn antigen have been successfully xenografted into mice and 
were responsible by enhancing the metastatic capability of cancer cells  [18, 97]. Recently, 
the colon cancer cell line LSC that naturally expresses the STn antigen was also 
xenografted into nude mice and shown to be inhibited by  anti-STn monoclonal antibody 
3P9   [108]. However, to our knowledge, the direct xenotransplantation of a STn-positive 
bladder tumor into nude mice had not yet been attempted. 
Xenograft models have been used as standard model predicting efficacy and toxicity 
of cancer chemotherapeutic agents before entering the clinic due to its ease, low cost, and 
faster establishment, when compared to the genetic engineered models  [109]. In 
opposition to the xenografts established from cultured cancer cells, where primary cells 
adapt and suffer a process of natural selection through several passages in culture, direct 
xenotransplantation of human tumors’ fragments preserves original cell heterogeneity, 
tumor phenotype and malignant potential of human tumors  [110, 111]. Patient derived 
xenografts mimic the heterogeneity of human cancers and have demonstrated superior 
correlation of chemosensitivity and specificity data for individualized therapy  [109] with 
prediction rates of 90% and 97% for chemosensitivity and chemoresistance, respectively  
[112]. Previous studies have used cancer xenograft models as a platform for molecular and 
histopathology studies and therapeutic development with good results in term of success 
rates, preservation of the original characteristics of the primary tumor and predictive 
value of the model  [113–116]. Preserving the primary tumor characteristics is essential to 
ensure the original glycosylation patterns, since they are dependent, among other factors, 
on the way the tumor microenvironment regulates the expression of multiple genes within 
the glycosylation pathways  [117–119]. Still, no evidences have been presented regarding 
to the preservation of STn expression patterns of the original tumor in direct xenografts. 
As such, the goal of this study was to establish a direct human bladder cancer 
xenograft model in nude mice conserving STn expression of the primary tumor. Such 
model is regarded of primary importance to identify drugs and treatment regimens that 
would better serve patients with STn-positive MIBC. It may also be used to test novel 
therapies and as a platform to identify markers of tumor response and resistance to drugs.  
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Material and methods 
Formalin-fixed paraffin embedded tissues of a MIBC and its first, second and third 
generation xenografts in nude mice were developed by the Experimental Pathology and 
Therapeutics Group of IPO-Porto and made available for this work. The clinicopathological 
characterization of the primary tumor, the animals used for this work, the methodology 
for the establishment of the xenografts, the histological and immunohistochemistry 
analysis were as follows: 
 
Primary tumor 
A fresh tumor specimen was collected at the time of therapeutic radical cystectomy 
performed to a 69-year-old man with muscle-invasive urothelial carcinoma (MIBC) at IPO 
Porto that was neither submitted to preoperative radiotherapy nor neoadjuvant 
chemotherapy. After surgical excision, tumor tissue was immediately transported to the 
laboratory in RPMI medium with 1% penicillin/streptomycin. Part of tumor was cut into 
pieces of 1-2 mm3 and engrafted in mice while other was fixed in formalin and processed 
for histological and immunohistochemical analysis. 
This study was approved by the ethical committee of the IPO-Porto and informed 
consent was obtained from the patient. 
 
Animals 
The experiments were carried out in accordance with the National and European 
Convention for the Protection of Animals used for experimental and other scientific 
purposes and related European Directive (2010/63/EU). Nine male nude mice (strain: 
N:NIH(s) II-nu/nu), aged 6-7 weeks, obtained from the Animal Experimental Unit at 
IPATIMUP, Porto, Portugal, were transplanted with human primary tumor. After tumor 
establishment, 3 and 12 nude mice were used for the second and third passage 
respectively as illustrated in Figure 13. The animals were maintained under sterile 
conditions throughout the experiment (temperature 24 ± 2 °C, relative humidity 55 ± 5% 
and a 12 h photoperiod) in polycarbonate cages. They were fed sterilized autoclave rodent 
feed and water ad libitum.  
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Figure 13 | MIBC tissue was used to establish the xenograft model. After engraftment phase 
(P0), xenografts were expanded in a group of nude mice as described in Materials and Methods. P1 
and P2 represent xenografts of the second and third generations, respectively. The red crosses 
represents sacrificed mice without tumor growth, the small red balls represents the tumors 
implanted, whereas the bigger ones represents tumor growth. 
 
Establishment of xenografts 
A sample of the patient tumor were cut into 1-2 mm3 fragments and individual 
pieces were implanted subcutaneously through small horizontal incisions in the scapular 
regions of anesthetized nude mice. The tumors were excised when they reached a size of 
approximately 1.5 cm3, cut into 1-2 mm3 fragments and transplanted to another group of 
mice (P1 and P2) using the same method.  Animals were anesthetized using isoflurane 
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according to the manufacturer's instructions at the time of transplantation and tumor 
removal. 
After transplantation, all mice were observed for development of a palpable mass 
and tumor growth was assessed using a caliper  to determine height(h), width(w) and 
depth(d) twice a week. Tumor volume was estimated using the formula:  
             
 
 
       as described elsewhere  [120]. 
Tumor doubling time (DT) was used for quantification of tumor growth rate. DT was 
calculated as the time period (t) when the tumor volume was twice (v2) the initial volume 
(v1) during the exponential phase of tumor growth, using the formula:              
    
  
  
  defined by Schwartz  [121].  
 
Histological analysis 
Tissue from the tumors and mice organs were fixed in 10% phosphate buffered 
formalin, embedded in paraffin, serially sectioned at 3 µm and stained with hematoxylin-
eosin (H&E) for histological examination. Tumors were analyzed in terms of histologic 
type, degree of differentiation, nuclear atypia and extension of invasion whereas mice 
organs were accessed for tumor metastasis.  
 
Immunohistochemical analysis 
Primary tumor and the tumors grown in the three passages were tested for 
molecular markers expression through immunohistochemical analysis. Formalin-fixed, 
paraffin-embedded (FFPE) tumor sections (3 µm) were tested with primary antibodies 
against p53 (clone DO -7;Dako; 1: 200), p63 (clone 4A4; Dako ; 1:300), Ki-67 (clone Mlb-1; 
Dako; 1:150), CK20 (clone Ks20.8; Novocastra; 1:150) and STn (anti-STn TKH2 
monoclonal antibody  [122]; 1:5 from culture supernatant) using polymer-HRP detection 
method (Power vision). The sections were initially dewaxed in xylene and rehydrated in 
graded alcohols. Heat-induced epitope retrieval using citrate buffer was carried out 
according antibody manufacturer’s instructions. Endogenous peroxidase activity was 
inhibited by immersing sections in 0.6% H2O2 in distilled water for 20 minutes. Sections 
were rinsed in PBS-Tween prior to incubation with bovine serum albumin solution (20 
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minutes) to inhibit non-specific binding. PBS was subsequently used to wash sections 
between stages. Sections were then incubated with the primary antibodies against p53, 
p63 Ki-67, CK20 and STn. The bound primary antibody was detected by the addition of 
secondary antibody conjugated with horseradish peroxidase polymer (Power Vision poly-
HRP-anti Ms/Rb/R IgG) for 30 minutes and DAB substrate for 7 minutes. Then, the slides 
were counterstained with hematoxylin and mounted. Positive and negative controls were 
run simultaneously with tumor specimens. The expression of STn was further validated by 
observing the loss of reactivity with anti-STn monoclonal antibody TKH2 after treatment 
of the tumor with a neuraminidase from Clostridium perfringens (Sigma-Aldrich), as 
previously described by Marcos et al.  [94]. This treatment was responsible by removing 
the sialic acid from STn which impaired antibody recognition.   
The staining patterns were assessed by two independent observers (one of them a 
pathologist) using standard light microscope. Positive staining was considered when more 
than 10% of tumor cells showed reactivity. Stain intensity and percentage of tumor cells 
stained were recorded to each tumor marker and classified into categories A (< 25%), B 
(25-50%), C (50-75%), D (>75%) according to the number of positive tumor cells stained. 
The Wilcoxon sign rank test was applied to disclose differences between the levels of 
expression of tumor markers in the primary tumor and xenografts using Stata 12.1 for 
Windows (Stata Corp LP, Texas, USA).  
  
Protein extraction and Western blot 
Proteins were extracted from FFPE tissues using the Qproteome FFPE tissue kit 
(Qiagen). The amount of protein in each extract was estimated with DC protein assay kit 
(BioRad). Thirty micrograms of protein were separated by 4–16% gradient SDS–PAGE 
under reducing conditions and transferred onto 0.45 µm nitrocellulose membranes (GE 
Healthcare). Membranes were blocked with  1% carbohydrate depleted carbo-free 
solution (Vector Laboratories) for 1 hour at room temperature, incubated overnight at 4ºC 
with anti-STn TKH2 monoclonal antibody in culture supernatant, washed with TBS-T for 
30 minutes, and finally incubated for 45 minutes with goat anti-mouse IgG1 heavy chain 
horseradish peroxidase conjugate (Abcam; 1:35,000 in TBS). After washing, the bound 
antibodies were revealed by chemiluminescence using the ECL prime Kit (BioRad). 
Samples previously de-sialylated with as previously described by Marcos et al.  [94] were 
used as controls. 
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Results 
A direct human bladder cancer xenograft model was established (P0) and expanded 
(P1) in a group of nude mice until the third passage (P2), as schematized in Figure 13. 
The primary tumor used to establish the xenografts was obtained after radical 
cystectomy performed to a 69-year-old man diagnosed with invasive urothelial bladder 
cancer (pT3aN0M0). Histologic analysis presented a high grade urothelial carcinoma 
invading the muscularis propria and perivesical fat (pT3a). Regional lymph nodes and 
surgical margins were tumor free. Preliminary analysis by immunohistochemistry showed 
an intense and diffuse STn-expression pattern throughout the tumor (>70% positive) 
including in cells invading the muscle and fat layers. Few cells in the tumor-adjacent 
mucosa were also positive whereas stromal cells were negative. Staining was observed in 
the cytoplasm, mainly in the trans Golgi region and was particularly intense in the cell 
membrane, thus in accordance with our previous observations  [11]. 
In the first passage (P0), one out of nine mice presented tumor growth, which 
corresponded to a success take rate of 11%. The percentage of successful engraftment 
increased in sequential passages (2/3 in P1 and 12/12 in P2). The lag period was 4 
months for the first passage, and became shorter in subsequent passages, 5-9 weeks in the 
second and around 9 weeks in the third (Figure 14). Of note, despite some variance in the 
lag period between xenografts in the third passage, the tumor growth curves became more 
similar and constant among them, suggesting consistency in tumor growth. Tumor 
doubling time was approximately 6 days in the first generation and became longer in 
subsequent passages, around 10 and 14 days in the second and third passage respectively. 
The mice bearing tumors in the three passages had no macroscopic evidence of invasion of 
adjacent tissues at the time of tumor excision neither metastasis were found at the time of 
sacrifice.  
The establishment of tumors with high successful take rate and homogeneous 
growth, suitable for drug testing studies, was achieved at the third generation (P2) 8 
months after the xenotransplantation of the primary tumor.  
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Figure 14 | Tumor growth curve for the first (P0), second passage P1 (a and b) and third 
generation (P2) xenografts. In the first passage the xenograft presented a lag period of 13.5 
weeks before progressive tumor growth was observable. The time between transplantation and 
palpable tumor growth became shorter on the subsequent passages, 5 (P1a) and 9 (P1b) weeks in 
the second passage and 6 weeks in the third. Xenografts growth rate was regular in the three 
passages. Different lag periods observed for P1 (P1a and P1b) denote instability in the adaptation 
of the tumors to the host in the second generation. Both the tumor lag periods and growth rates 
became stable in the third generation. Tumor volume was plotted on a logarithmic scale. 
 
Histological and immunohistochemical analysis of the primary 
tumor and xenografts  
The morphological characteristics of xenografts were analyzed and compared with 
the primary tumor. The histology of the original tumor revealed an invasive urothelial 
bladder carcinoma with high nuclear-to-cytoplasmic ratio, nuclear atypia and presence of 
mitotic figures. The resulting xenografts presented identical histologic features to those 
observed in the primary tumor, particularly in terms of cellular type and grade of atypia. 
The percentage of necrosis was around 10% in both primary tumor and xenografts and 
some xenografts presented scamous differentiation that ranged between 10 and 25%.  
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In addition to the neoplasic cells, the first passage xenograft also presented a cyst 
covered by a layer of epithelial like cells, which also enclosed the tumor. This vesicle-like 
sac was composed by an epithelial lining layer of variable number of cells and dense 
connective tissue and represents the heterogeneity of the tumor cells implanted. This 
structure was no longer present in subsequent passages, denoting some degree of clonal 
selection for malignant cells.  
The primary tumor and xenografts were further evaluated by 
immunohistochemistry in relation to proliferation (Ki-67), aggressiveness (p53) and 
differentiation (p63 and CK20) markers (Figure 15) and the STn antigen expression 
(Figure 16), whose over-expression is common in aggressive bladder cancer  [123]. 
 
Figure 15 | Histology and tumor molecular markers (p53, p63, Ki-67, CK20) 
immunoexpression of primary tumor (Pt) and first (P0), second (P1), third (P2) generation 
xenografts (original magnification x200). No major differences are seen in the tumor structure 
and cancer cells markers expression between the original tumor and the xenografts. However in the 
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case of p53 and Ki-67 expression, an increase was observed in xenografts when compared with the 
original tumor, suggesting a more aggressive and proliferative phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 | A) STn immunoexpression in primary tumor and xenografts in first (P0), second 
(P1) and third generations (P2) (original magnification x200). STn expression was maintained, 
even though decreased, in the xenografts.  
 
Both the primary and the xenografted tumors (P0, P1 and P2) were positive for 
these markers, reinforcing the homology suggested by histological analysis (Figures 13 
and 14). Likewise, the primary tumors and the xenografts shared a strong and diffuse 
expression of p63 and CK20 (>75% of the tumor area), representing similar degrees of 
differentiation (Table 2 and Figure 17). However, significant variations were observed in 
the levels of p53, Ki-67 and STn between the primary tumor and xenografts and also 
between sequential passages (Figure 17).  In general, the percentage of p53 positive cells 
was higher in xenografts when compared to the primary tumor (25-75% and 10-25% 
respectively). This tendency was particularly pronounced in the third generation 
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xenografts. The levels of Ki-67 immunoexpression were also significantly elevated in P0 in 
comparison to the primary tumor (50-75% and 25-50% respectively). Some variations in 
Ki-67 expression were also observed between xenografts in different passages (Figure 
17). The P0 presented the highest proliferative index, in agreement with the lower tumor 
doubling time presented by the first generation xenografts (Figure 13). The expression of 
Ki-67 decreased in P1 to levels similar to the initial tumor but increased again in P2. 
Altogether, these data suggests that the xenograft establishment process may be 
accompanied by the selection of a more aggressive and proliferative phenotype 
characterized by a significant over-expression of Ki-67 and p53 (Table 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 | Immunoexpression of tumor markers p53, p63, Ki-67, CK20 and STn in the 
primary tumor (Pt) and first (P0), second (P1) and third (P2) generation xenografts. The 
expression levels of p63 and CK20 presented by the primary tumor were conserved in the 
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xenografts denoting similar levels of differentiation. The expression of p53 was increased in the 
xenografts in relation to the primary tumor and increased with sequential passages. The Ki-67 
increased in P0 but decreased in P1 denoting a process of adaptation of the tumor cells to the host. 
The proliferation then increased in P2, suggesting the selection of proliferative clones. Altogether, 
STn antigen expression was decreased in the xenografts in relation to the primary tumor and 
decreased with the passages. 
 
Table 2 | Comparison between the immunoexpression of tumor markers p53, p63, Ki-67, CK20 and 
STn in the primary tumor and the third generation xenografts (P2), that showed high and 
homogeneous growth rates. 
 
a Wilcoxon sign rank  
Percentage of expression: A (< 25%), B (25-50%), C (50-75%), D (>75%) 
 
Levels of 
Expression  
Primary Tumor P2 Xenografts 
 
p53 
   
A 1 (100%) 1 (8%) 
 
B 0 4 (33%) p-value 
C 0 6 (50%) 0.0021 
D 0 1 (8%) 
 
p63 
   
A 0 0 
 
B 0 0 p-value 
C 0 1 (8%) 0.3173 
D 1 (100%) 11 (92%) 
 
Ki-67 
   
A 0 0 
 
B 1 (100%) 6 (50%) p-value 
C 0 6 (50%) 0.0143 
D 0 0 
 
CK20 
   
A 0 0 
 
B 0 0 p-value 
C 0 1 (%) 0.3173 
D 1 (100%) 11 (92%) 
 
STn 
   
A 0 5 (42%) 
 
B 0 6 (50%) p-value 
C 1 (100%) 1 (8%) 0.0020 
D 0 0 
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The STn antigen, that was highly expressed in the primary tumor (>75% of the 
area), was also detected in xenografts (Figure 16); however its levels decreased with 
xenotransplantation and along consecutive passages. Since the STn antigen is a post-
translational modification common to several cell-surface glycoproteins, we have also 
evaluated whether the protein pattern of expression remained conserved in the P2 
xenografts by western blot (Figure 18). Both blots presented a dominant band at 
approximately 55 kDa and several high-molecular weight bands above 75 kDa that were 
no longer observable in control experiments with desialylated protein extracts. Therefore, 
even though decrease in relation to the primary tumor, the expression pattern of STn 
remains conserved in the P2 xenografts proteins (Table 2).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 | Western blot for the proteins expressing the STn antigen in primary tumor and 
P2 xenografts. Similar protein patterns were observed in both cases; differences in staining 
intensities are thought to results from the lower expression of STn in xenografts. STn+ refers to the 
native protein extracts while STn- refers to protein extracts after desialylation with a 
neuraminidase, which impairs recognition by anti-STn monoclonal antibody. The absence of 
immunoreactivity in the STn- bands confirms the specificity of the recognition pattern. 
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Discussion 
We recently reported that a significant percentage of MIBC expressed the STn 
carbohydrate antigen, a post-translational modification of cell-surface proteins 
responsible by enhancing the motility and invasive capability of bladder cancer cells  [11]. 
Therefore, the goal of this study was to establish a direct human bladder cancer xenograft 
model in nude mice conserving STn expression of the primary tumor. Such model is 
regarded of primary importance to identify drugs and treatment regimens  [124] that 
would better serve patients with STn-positive MIBC.  
Herein, we describe the transplantation of freshly collected STn-positive MIBC 
fragments directly into nude mice that were then passed to other mice without 
compromising the histological and molecular nature of the original tumor. Tumor take 
rate and the consistency in growth rates following implantation, critical aspects of 
xenograft models, have also been evaluated. In our study, one sample of MIBC was 
implanted into 9 nude mice with a success take rate of 1/9 (~11%) that increased in 
subsequent passages. Analogous success rates have been described in previous studies 
using similar methods for establishing bladder cancer xenografts, independent of primary 
tumor stage. Namely, Hay et al., that reported a success take rate of 7/48 (15%) after 
bilateral transplantation of bladder cancer specimens into 5 immunocompetent mice 
previously subjected to thymectomy and whole body radiation  [125]. Kovnat et al., using 
the same procedure reported a success take rate of 8/33 (24%) and 20/53 (38%)  [126, 
127]. More recently, Abe et al. reported an overall success rate in xenograft establishment 
of 62.5% (15/24) using severe combined immunodeficient mice and one or two fragments 
of 4-5 mm3 per mice  [128]. In order to increase the tumor take rate, some aspects may be 
modulated in future xenografts, specifically the number and volume of the fragments 
implanted.  
The lag period was 4 months for the first generation xenografts and became shorter 
on the subsequent passages, 5-9 weeks in the second and around 9 weeks in the third. The 
longer lag period observed in the first passage might be explained by the presence of a low 
fraction of clonogenic cells in the fragment implanted and the need to adapt and grow in a 
new environment. The xenografts growth rates were also different between passages, 
however, they became similar between xenografts of the same passage in the third 
generation (P2), suggesting growth consistency. This aspect enables comparison of tumor 
growth between groups and assessment of tumor response to chemotherapeutic drugs. 
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These results are in agreement with a previous reports using similar methods (human 
bladder cancer specimen nude mice and subcutaneous implantation) to obtain xenografts 
from bladder tumors  [128] as well as with other cancer xenograft models  [111, 116, 124, 
129].  
Histological analyses have demonstrated high similarity between primary tumor 
and xenografts in terms of cellular type and grade of atypia, suggesting that the phenotype 
of the primary tumor is preserved during tumor establishment and expansion in nude 
mice. This observation was reinforced by the detection of similar levels of differentiation 
markers p16 and CK20. However, variations in the expression of p53 and Ki-67 were 
observed between the primary tumor and the xenografts and between different passages. 
A comparison between primary tumor and third generation xenografts has further 
highlighted an increased expression of p53 and Ki-67, suggesting a tendency to select of 
the most aggressive and rapidly growing cells from a heterogeneous primary tumor 
during engraftment process. In accordance with these observations, several publications 
have described that certain cell populations of the primary tumor can be amplified by the 
xenografting process and may represent the natural tumor evolving process towards a 
more aggressive phenotype with higher potential to adapt and metastasize  [130, 131].  
Along with the ability to obtain high take rate and stable tumor growth, these events 
reinforced the value of third generation xenografts and subsequent passages as a good 
model for cancer drug testing. 
We also observed that xenografts reproduced the STn expression pattern observed 
in the primary tumor, thereby creating the first in vivo bladder tumor model expressing 
this antigen. The development of non-human models expressing the STn antigen has been 
a particularly challenging enterprise. Despite the pan-carcinoma nature of this antigen  
[55], in vivo models that mimic clinical setting of tumors expressing this antigen are still 
missing and the direct xenotransplantation of a STn-positive human bladder tumor cells 
into nude mice had not yet been attempted. In our model STn antigen expression 
decreased in xenografts in comparison to the primary tumor, a decrease that became more 
pronounced in the third generation which also showed a more prominent proliferative 
phenotype. Such observations reinforce our previous findings that, despite being 
associated with proliferative phenotypes, cells expressing the STn antigens are commonly 
found in non-proliferative invasive areas of the tumor. Nevertheless, the third generation 
xenografts conserved significant STn expression and presented an STn-expressing 
glycoprotein profile similar to the primary tumor. Studies are ongoing to determine the 
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nature of these proteins and disclose the environmental factors that promote STn 
expression in bladder cancer.    
Given their capability to recapitulate the histological and molecular nature of the 
primary tumor, the STn-expressing bladder cancer xenografts show potential as a model 
to determine the adequate treatment schemes for these tumors, test new drugs and 
identify prognostic biomarkers. Similar xenograft models for other cancers have shown a 
“remarkable correlation between drug activity in the model and clinical outcome” and 
have already been transpose into the clinical practice  [116]. Altogether we believe that 
this approach may also be useful in the context of MIBC. Additional work involving a larger 
number of patients is ongoing to optimize the model and further explore its potential in 
drug testing. Given the pancarcinoma nature of STn antigen expression, its association 
with invasion and metastases, these findings may constitute valuable insights for other 
tumors. 
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Conclusions 
Aiming to determine the association of STn with invasion, proliferation and 
metastasis, primary bladder tumors and lymph node and distant metastasis were 
screened for the STn expression, by immunohistochemistry. This confirmed the 
association of STn with the referred clinical settings, corroborating the aggressive nature 
of this antigen and its potential as a prognostic biomarker in bladder cancer. Furthermore, 
it was also confirmed by Western blot that high-molecular weight proteins are the major 
carriers of STn in primary tumors. Conversely, metastasis showed a pattern composed of 
low-molecular weight proteins (<25 kDa), that appear to result from the proteolytic 
cleavage of high-molecular weight species. Future studies should be conducted to disclose 
a possible metastasis-associated glycoprotein profile. 
The second part of the work aimed to validate a STn-expressing bladder cancer 
xenograft as a model for drug testing and identification of prognostic biomarkers. It was 
observed that xenografts retained the histological nature of the primary tumor and similar 
levels of differentiation markers p63 and CK20. However, p53 and Ki-67 levels increased 
along passages while STn expression decreased, suggesting a selection of the most 
proliferative clones. Nevertheless, the glycoproteins STn-expression pattern of the 
primary tumor was conserved in the xenografts. Taken together, the generated data 
suggests that xenografts mimic the molecular nature of the primary tumor, including STn 
expression. 
Altogether, important insights have been provided about the clinical relevance of 
STn in bladder cancer that will help guiding the development of novel STn-based 
therapies.  
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Future work and perspectives 
This work has provided important insights about the clinical relevance of STn in 
bladder cancer. Future studies should be conducted in a larger number of patients 
including different clinicopathological features, such as precursor lesions, carcinoma in 
situ (CIS) and inflammatory disease, to isolate cancer-associated patterns. Associations 
with response to therapeutics and the expression of other biomarkers of aggressiveness 
disease may also help to determine the group of patients better served by an STn-based 
therapeutics.  
Moreover, the identification of the STn expressing proteins will be necessary to 
disclose the biologic role of this antigen. It would be also imperative to determine the 
nature of the low-molecular weight proteins and their role in metastasis. The validation of 
a protein profile associated with metastasis will also require the evaluation of a larger 
number of patients, including samples of metastasis. Altogether, this information will 
create the clinical basis for the development of therapeutics for aggressive bladder cancer 
malignant disease.   
The development of novel drugs requires animal models able to mimic the primary 
tumor. This work suggests that patient derived STn-positive xenografts may reflect the 
histologic and molecular nature of the primary tumor, however showing signs of clonal 
selection towards more aggressive proliferative phenotypes. The validation of such a 
model requires the histologic, proteomic and genomic comparison between the model and 
the primary tumor in a larger number of patients. Given the pan-carcinoma nature of STn 
antigen expression and its association with invasion and metastasis, the optimization of 
the model may constitute valuable insights for other tumors. 
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